KR20220159536A - Manufacturing method of Medical Herb Tea for Preventing and Alleviating Dementia - Google Patents
Manufacturing method of Medical Herb Tea for Preventing and Alleviating Dementia Download PDFInfo
- Publication number
- KR20220159536A KR20220159536A KR1020210066936A KR20210066936A KR20220159536A KR 20220159536 A KR20220159536 A KR 20220159536A KR 1020210066936 A KR1020210066936 A KR 1020210066936A KR 20210066936 A KR20210066936 A KR 20210066936A KR 20220159536 A KR20220159536 A KR 20220159536A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- parts
- hours
- water
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 239000000284 extract Substances 0.000 claims abstract description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000015092 herbal tea Nutrition 0.000 claims abstract description 36
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 31
- 240000007594 Oryza sativa Species 0.000 claims abstract description 22
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 22
- 235000009566 rice Nutrition 0.000 claims abstract description 22
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract description 16
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 16
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 15
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 12
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 10
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 10
- 229940010454 licorice Drugs 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 235000006533 astragalus Nutrition 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 241000122821 Aspergillus kawachii Species 0.000 claims abstract description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 244000179886 Moringa oleifera Species 0.000 claims description 25
- 235000011347 Moringa oleifera Nutrition 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 15
- 241001474374 Blennius Species 0.000 claims description 15
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 229910052709 silver Inorganic materials 0.000 claims description 13
- 239000004332 silver Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 244000019194 Sorbus aucuparia Species 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052737 gold Inorganic materials 0.000 claims description 10
- 239000010931 gold Substances 0.000 claims description 10
- 210000004209 hair Anatomy 0.000 claims description 10
- 241000208688 Eucommia Species 0.000 claims description 9
- 210000003056 antler Anatomy 0.000 claims description 9
- 241000212948 Cnidium Species 0.000 claims description 8
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 8
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 8
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 8
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 8
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 8
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 8
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 8
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 8
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 8
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 229940107131 ginseng root Drugs 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 7
- 244000063299 Bacillus subtilis Species 0.000 claims description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 235000020687 goji berry extract Nutrition 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- 240000002045 Guettarda speciosa Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 235000006414 serbal de cazadores Nutrition 0.000 claims description 6
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 5
- 235000009790 Sorbus aucuparia Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 3
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 2
- 240000001810 Angelica gigas Species 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract description 2
- 241000533367 Cnidium officinale Species 0.000 abstract description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 abstract description 2
- 241000657480 Crataegus pinnatifida Species 0.000 abstract description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract description 2
- 241001080798 Polygala tenuifolia Species 0.000 abstract description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 2
- 244000237330 gutta percha tree Species 0.000 abstract description 2
- 239000012452 mother liquor Substances 0.000 abstract 2
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241001092040 Crataegus Species 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 6
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 6
- 241001122767 Theaceae Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000000554 iris Anatomy 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 102000012440 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 229940022698 acetylcholinesterase Drugs 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 244000061520 Angelica archangelica Species 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 241000123107 Phellinus Species 0.000 description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- QDFFAXSMLUUJSG-UHFFFAOYSA-N 1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2 QDFFAXSMLUUJSG-UHFFFAOYSA-N 0.000 description 2
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 2
- ONUSCCKLNWURMA-UHFFFAOYSA-N 3,8-dimethylnaphtho[2,1-g][1]benzofuran-4,5-dione Chemical compound O=C1C(=O)C2=CC=C3C(C)=CC=CC3=C2C2=C1C(C)=CO2 ONUSCCKLNWURMA-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- 244000205574 Acorus calamus Species 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 2
- 241000193422 Bacillus lentus Species 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 235000011996 Calamus deerratus Nutrition 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- UPCWCCRFMPIOAP-UHFFFAOYSA-N Hydroxytanshinone Chemical compound C1=CC(C(CCC2O)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 UPCWCCRFMPIOAP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241001468192 Leuconostoc citreum Species 0.000 description 2
- 235000017617 Lonicera japonica Nutrition 0.000 description 2
- 244000167230 Lonicera japonica Species 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- 235000002322 Monascus purpureus Nutrition 0.000 description 2
- 244000113306 Monascus purpureus Species 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 241000178960 Paenibacillus macerans Species 0.000 description 2
- 241000194105 Paenibacillus polymyxa Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- 241001092391 Sorbus Species 0.000 description 2
- 241000193395 Sporosarcina pasteurii Species 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- ZPNKIIKAXNCFKF-UHFFFAOYSA-N [I+].CC(=O)SCC[N+](C)(C)C Chemical compound [I+].CC(=O)SCC[N+](C)(C)C ZPNKIIKAXNCFKF-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- YFDKIHAZVQFLRC-UHFFFAOYSA-N methuyl tanshinonate Chemical compound C1=2OC=C(C)C=2C(=O)C(=O)C2=C1C=CC1=C2CCCC1(C)C(=O)OC YFDKIHAZVQFLRC-UHFFFAOYSA-N 0.000 description 2
- 235000008345 mountainash Nutrition 0.000 description 2
- -1 neotanshinone A B C Chemical compound 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 239000001054 red pigment Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 229930189533 tanshinol Natural products 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- WTEXYKPGDKLLCW-KCSPPWDSSA-N (3Z,9aR)-3-(1-hydroxyhexylidene)-9a-methyl-6-[(E)-prop-1-enyl]furo[3,2-g]isoquinoline-2,9-dione Chemical compound CCCCC\C(O)=C1\C(=O)O[C@]2(C)C1=Cc1cc(\C=C\C)ncc1C2=O WTEXYKPGDKLLCW-KCSPPWDSSA-N 0.000 description 1
- AQTJNEHGKRUSLT-ODTNPMSZSA-N (3s,3ar,9ar)-9a-methyl-3-octanoyl-6-[(e)-prop-1-enyl]-3,3a,4,8-tetrahydrofuro[3,2-g]isochromene-2,9-dione Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCCCC)C2=C1COC(\C=C\C)=C2 AQTJNEHGKRUSLT-ODTNPMSZSA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- VUIHARLRBGHPEA-UHFFFAOYSA-N 4,4,8-trimethyl-2,3,8,9-tetrahydro-1h-naphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound O=C1C2=CC=C(C(CCC3)(C)C)C3=C2C(=O)C2=C1C(C)CO2 VUIHARLRBGHPEA-UHFFFAOYSA-N 0.000 description 1
- QZQXRZXYWVQWAY-UHFFFAOYSA-N 8-(9h-fluoren-9-ylmethoxycarbonylamino)octanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCCCCCC(=O)O)C3=CC=CC=C3C2=C1 QZQXRZXYWVQWAY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000005827 Arthrocnemum glaucum Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193414 Bacillus fastidiosus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241001481710 Cerambycidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ZJJITLRIOBUSGZ-UHFFFAOYSA-N Isocryptotanshinone Natural products CC1CC2=C(O1)C(=O)c3c4CCCC(C)(C)c4ccc3C2=O ZJJITLRIOBUSGZ-UHFFFAOYSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- QCUYNKMUDZHGNK-UHFFFAOYSA-N Monascorubramine Natural products CCCCCCCC(=O)C1=C2C=C3C=C(NC=C3C(=O)C2(C)OC1=O)C=CC QCUYNKMUDZHGNK-UHFFFAOYSA-N 0.000 description 1
- 241001052469 Monascus kaoliang Species 0.000 description 1
- 241000030999 Monascus pilosus Species 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 241001504654 Mustela nivalis Species 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 241000178961 Paenibacillus alvei Species 0.000 description 1
- 241000178959 Paenibacillus durus Species 0.000 description 1
- 241001310339 Paenibacillus popilliae Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000008681 Phellinus linteus extract Substances 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 244000171085 Polyporus umbellatus Species 0.000 description 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 235000003042 Salicornia europaea Nutrition 0.000 description 1
- 240000002625 Salsola soda Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 241000593948 Sargassum serratifolium Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000004489 Sorbus commixta Nutrition 0.000 description 1
- 241001115347 Sorbus commixta Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- ORJQJZWWJUNMQV-UHFFFAOYSA-N ankaflavin Natural products CCCCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC ORJQJZWWJUNMQV-UHFFFAOYSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- QHGPIJMPUOVBOL-UHFFFAOYSA-N isotanshinone IIA Natural products O=C1C2=CC=C(C(CCC3)(C)C)C3=C2C(=O)C2=C1C(C)=CO2 QHGPIJMPUOVBOL-UHFFFAOYSA-N 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000009472 lonicerae flos Substances 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- XXKNHBAFFJINCK-RVEJDSBJSA-N monascin Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCC)C2=C1COC(\C=C\C)=C2 XXKNHBAFFJINCK-RVEJDSBJSA-N 0.000 description 1
- GFSMXLMQRWMHON-UHFFFAOYSA-N monascin Natural products CCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC GFSMXLMQRWMHON-UHFFFAOYSA-N 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- GIKQHOXMDCDAPT-UHFFFAOYSA-N monascusone B Natural products CC=CC1=CC2=C(CO1)C(=O)C3(C)OC(=O)C(C3C2)C(=O)C GIKQHOXMDCDAPT-UHFFFAOYSA-N 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 239000000974 natural food coloring agent Substances 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021039 pomes Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- OVOAWDOEFJNCGI-UHFFFAOYSA-N rubropunctatamine Natural products CCCCCC(=O)C1=C2C=C3C=C(NC=C3C(=O)C2(C)OC1=O)C=CC OVOAWDOEFJNCGI-UHFFFAOYSA-N 0.000 description 1
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 description 1
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229930183325 senkyunolide Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 description 1
- 229950006755 xanomeline Drugs 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/22—Drying or concentrating tea extract
- A23F3/24—Drying or concentrating tea extract by freezing out the water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/08—Oxidation; Fermentation
- A23F3/10—Fermentation with addition of microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/18—Extraction of water soluble tea constituents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/22—Drying or concentrating tea extract
- A23F3/26—Drying or concentrating tea extract by lyophilisation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
- A23F3/32—Agglomerating, flaking or tabletting or granulating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/41—Shearing
Abstract
Description
본 발명은 치매 예방 및 개선용 한방차의 제조방법에 관한 것으로, 보다 상세하게는 치매 개선 효과가 우수하며, 맛이 우수한, 치매 예방 및 개선용 한방차의 제조방법에 관한 것이다.The present invention relates to a method for manufacturing herbal tea for preventing and improving dementia, and more particularly, to a method for manufacturing herbal tea for preventing and improving dementia, which has an excellent effect on improving dementia and has excellent taste.
최근 산업화와 환경의 변화 속에서 현대인들은 다양한 원인에 의한 면역력 저하로 인해 각종 질병에 노출되어 있으며, 이러한 질병 치료를 위해 막대한 비용을 소모하고 있다. 특히, 최근 오염된 공기 및 신생활 변화 등의 이유로 알러지성 질환은 여러 알러지 유발인자에 의해 인체 면역체계를 과도하게 항진시켜 대식세포와 같은 면역세포에서 TNF-α(tumor necrosis factor-α), IL-1(interleukin-1), IL-6(interleukin-6), 프로스타글란딘(prostagladin), 류코트리엔(luecotriene), MMP-9(matrix metalloproteinase-9) 및 산화질소(nitric oxide, NO)와 같은 염증유발 물질을 과도하게 유도하여 이는 염증반응으로 진행되어 여러가지 질병 및 면역 과민반응 증상 등을 일으키는 것으로 알려져 있다.Recently, in the midst of industrialization and environmental changes, modern people are exposed to various diseases due to reduced immunity due to various causes, and huge costs are consumed for the treatment of these diseases. In particular, due to recent polluted air and new life changes, allergic diseases excessively exaggerate the human immune system by various allergy triggers, resulting in TNF-α (tumor necrosis factor-α) and IL in immune cells such as macrophages. Inflammatory substances such as -1 (interleukin-1), IL-6 (interleukin-6), prostaglandin, leukotriene, MMP-9 (matrix metalloproteinase-9) and nitric oxide (NO) It is known that it induces excessively, which progresses to an inflammatory response, causing various diseases and immune hypersensitivity symptoms.
또, 이러한 면역체계의 붕괴로 인해 신경세포의 손상 및 손실로 뇌기능이 손상되면서 치매가 발병하고 있으며 그 치매의 발병시기도 점차 빨라지고 있다.In addition, as the brain function is damaged due to the damage and loss of nerve cells due to the collapse of the immune system, dementia is developing, and the onset of dementia is gradually accelerating.
이러한 치매(dementia)는 정상적으로 생활해오던 사람이 다양한 원인에 인해 뇌기능이 손상되면서 이전에 비해 인지 기능이 지속적이고 전반적으로 저하되는 일종의 증후군으로, 병리학적으로는 신경세포의 손상 및 손실에 의해 기억, 집중, 언어 및 인지 등에 심한 장애가 오랜 시간 동안 점진적으로 진행되어 궁극적으로는 사망에 이르게 하는 뇌 질환이다. 이러한 치매의 원인 질환들로는 알츠하이머병(Alzheimer's disease), 혈관성 치매(Vascular dementia), 파킨슨씨 병(Parkinson's disease), 루이체 치매(Lewy body dementia), 무도병(Huntington's disease), 크루츠펠트-야콥병(Creutzfeldt-Jacob disease), 픽스씨 병(Pick's disease) 등이 알려져 있다.Dementia is a kind of syndrome in which cognitive function is continuously and generally deteriorated compared to the past as brain function is damaged due to various causes in people who have been living a normal life. Pathologically, memory is caused by damage and loss of nerve cells. It is a brain disease in which severe impairment in concentration, language, and cognition progresses gradually over a long period of time, ultimately leading to death. These causes of dementia include Alzheimer's disease, Vascular dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, Creutzfeldt-Jakob disease Jacob disease), Pick's disease, etc. are known.
그 중 알츠하이머 질환(AD)은 가장 흔한 퇴행성 뇌질환으로 점진적인 신경세포의 퇴화로 인해 인지능력 상실을 가져온다. 뇌 조직내 아밀로이드 플라그 및 아밀로이드로서 존재하는, 원섬유 형태의 아밀로이드-β 단백질 (Aβ)로 명명되는 39-43개 아미노산 펩티드의 축적을 특징으로 한다. 알츠하이머 병에서 Aβ 침착은 뇌의 신경세포 및 간질세포에게 유해하고, 그 결과 알츠하이머 병의 특징적인 특성인 뇌 염증 및 신경세포 사멸을 일으킨다.Among them, Alzheimer's disease (AD) is the most common degenerative brain disease and causes cognitive loss due to gradual degeneration of nerve cells. It is characterized by the accumulation of a 39-43 amino acid peptide termed fibrillar form of amyloid-β protein (Aβ), present as amyloid plaques and amyloid in brain tissue. In Alzheimer's disease, Aβ deposition is detrimental to neurons and interstitial cells in the brain, resulting in brain inflammation and neuronal death, which are characteristic features of Alzheimer's disease.
AD로 사망한 환자의 두뇌에서는 노인성 플라그(senile plaque)와 신경원섬유의 엉킴(neurofibrillary tangles)이 병리학적 특성으로 나타난다. 이 중 노인성 플라그는 세포 외부에 단백질과 죽은 세포 등이 축적되어 형성되는 것으로, 주 구성 성분은 아밀로이드-베타(Amyloid-β(Aβ)라는 펩티드이다.In the brains of patients who died of AD, senile plaques and neurofibrillary tangles appear as pathological features. Among them, senile plaque is formed by accumulation of proteins and dead cells outside cells, and its main component is a peptide called Amyloid-β (Aβ).
AD 환자의 주요 특징인 인지 작용의 점진적 상실은 비정상적으로 축적된 Aβ에 의해 유발되는 것으로 보인다. Aβ는 아밀로이드 전구 단백질(amyloid precursor protein: 이하 "APP"라 칭함)로부터 단백질 분해(proteolysis) 과정을 통해 생성된다. 전구물질인 APP는 β-세크라타제(BSCE) 및 γ-세크라타제에 의해 분해되어 Aβ가 생성된다. 그러나 α-세크라타제에 의해 APP가 절단될 경우 Aβ의 생성을 억제하고 신경세포 보호 효과를 나타내는 APPα의 생성을 유도하므로 α-세크라타제의 활성을 증가시키는 것이 알츠하이머병의 치료 또는 개선의 방법이다. 또한, 체내에서 SIRT1이 활성화되면 다양한 전사조절인자들을 탈아세틸화시킴으로써 α-세크라타제를 활성화시킨다.Progressive loss of cognitive function, a key feature of AD patients, appears to be caused by abnormally accumulated Aβ. Aβ is produced from amyloid precursor protein (hereinafter referred to as “APP”) through a proteolysis process. APP, a precursor, is degraded by β-secretase (BSCE) and γ-secretase to produce Aβ. However, when APP is cleaved by α-secretase, it inhibits the production of Aβ and induces the production of APPα, which has a neuroprotective effect. Therefore, increasing the activity of α-secretase is a method for treating or improving Alzheimer's disease. to be. In addition, when SIRT1 is activated in vivo, it activates α-secretase by deacetylating various transcriptional regulators.
한편 니코틴 수용체 저해제인 ABT-418, 무스카린 수용체 저해제인 자노멜린, 아세틸콜린 전구체인 레시틴, 아세틸-L-카르니틴, 금속 킬레이터인 데스페리옥사민, 리오퀴놀, 베타-쉬트 브레이커인 iAβ5, iAβ11, 항산화제인 비타민 E, 은행잎 추출물, 멜라토닌, 이데베논, sAPP 방출제인 니코틴, 아세틸콜린, 카바콜, 베타 세크라타제 또는 감마 세크라타제 저해제인 OM99-1, OM99-2, OM99-3, Z-VLL-CHO, 항염증제인 NSAIDs계 약물 등이 개발되고 있으나, 아직 효과가 약간의 병리적 증상을 완화 또는 진행 정도를 늦추는 정도로 생겨 미미하거나 자체의 독성 때문에 실제 적용이 어려운 물질이 대부분이어서 안정하며 효과적인 AD 치료제의 개발이 시급하다.On the other hand, nicotine receptor inhibitor ABT-418, muscarinic receptor inhibitor xanomeline, acetylcholine precursor lecithin, acetyl-L-carnitine, metal chelator desperioxamine, rioquinol, beta-sheet breaker iAβ5, iAβ11, Antioxidant vitamin E, ginkgo biloba extract, melatonin, idebenone, sAPP releaser nicotine, acetylcholine, carbachol, beta secretase or gamma secretase inhibitor OM99-1, OM99-2, OM99-3, Z-VLL -CHO and NSAIDs, which are anti-inflammatory drugs, are being developed, but most of them are insignificant because their effect is to alleviate some pathological symptoms or slow down the progress, or are difficult to apply in practice because of their toxicity, so they are stable and effective AD treatments. development is urgently needed.
대한민국등록특허공보 제10-2092509호(2020.03.23.)에는 치매 예방 및 개선용 식품 조성물이 개시되어 있다.Republic of Korea Patent Registration No. 10-2092509 (2020.03.23.) discloses a food composition for preventing and improving dementia.
상기 치매 예방 및 개선용 식품 조성물은 부작용이 적은 장점이 있지만, 치매 개선 효과가 미흡한 단점이 있다.The food composition for preventing and improving dementia has the advantage of having few side effects, but has a disadvantage in that the effect of improving dementia is insufficient.
본 발명의 목적은 치매 개선 효과가 우수한, 치매 예방 및 개선용 한방차의 제조방법을 제공하는 것이다.An object of the present invention is to provide a method for manufacturing herbal tea for preventing and improving dementia, which is excellent in improving dementia.
본 발명의 다른 목적은 맛이 우수한, 치매 예방 및 개선용 한방차의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for manufacturing herbal tea for preventing and improving dementia with excellent taste.
상기 목적을 달성하기 위하여 본 발명은 다음과 같은 수단을 제공한다.In order to achieve the above object, the present invention provides the following means.
본 발명은, 팽화미 30㎏에 물 60ℓ를 가하고 증자기를 이용하여 1.2㎏/㎠, 110℃에서 30분 동안 증자한 후, 백국균(Aspergillus Kawachii) 80g을 가하고 26℃의 항온항습기에서 40시간 동안 배양하여 입국을 제조하는 단계(단계 1); 상기 입국 4㎏, 물 6㎏ 및 효모 5g을 25~30℃에서 6일 동안 발효시켜 주모를 제조하는 단계(단계 2); 상기 주모 10㎏, 상기 입국 50㎏, 물 70㎏, 참당귀 뿌리 1200g, 가시오갈피 뿌리 1000g, 은행나무 잎 1000g, 황기 800g, 두충 700g, 오미자 열매 640g, 원지 뿌리 640g, 석창포 뿌리 640g, 산사나무 열매 640g, 녹각 640g, 천궁 뿌리 500g, 프락토올리고당 500g, 용안육 열매 400g, 단삼 뿌리 390g, 감초 300g 및 스테비아추출물 10g을 22~23℃에서 6개월 동안 발효시켜 제1 사입을 얻는 단계(단계 3); 상기 제1 사입 130㎏, 팽화미 100㎏, 물 160㎏ 및 정제효소 150g을 15~16℃에서 3일 동안 발효시켜 제2 사입을 얻는 단계(단계 4); 및 상기 제2 사입을 100~105℃에서 30~40분 동안 가열하여 치매 예방 및 개선용 한방차를 제조하는 단계(단계 5); 를 포함하는, 치매 예방 및 개선용 한방차의 제조방법을 제공한다.In the present invention, after adding 60 liters of water to 30 kg of puffed rice and increasing it using a steamer at 1.2 kg / cm 2 at 110 ° C. for 30 minutes, 80 g of Aspergillus Kawachii was added and the mixture was kept in a thermo-hygrostat at 26 ° C. for 40 hours. Culturing to prepare the entry (step 1); Fermenting 4 kg of the entry, 6 kg of water, and 5 g of yeast at 25 to 30 ° C. for 6 days to prepare main hair (step 2); 10 kg of above hair, 50 kg of above seaweed, 70 kg of water, Angelica root 1200 g, Ginkgo ginseng root 1000 g, Ginkgo leaf 1000 g, Astragalus 800 g, Eucommia 700 g, Schisandra fruit 640 g, Wonji root 640 g, Iris root 640 g, Hawthorn fruit 640g, antler horn 640g, cnidium root 500g, fructo-oligosaccharide 500g, longan meat 400g, dansam root 390g, licorice 300g, and stevia extract 10g fermented at 22-23 ° C. for 6 months to obtain a first stock (step 3); fermenting 130 kg of the first feed, 100 kg of puffed rice, 160 kg of water, and 150 g of purified enzyme at 15-16° C. for 3 days to obtain a second feed (step 4); and preparing herbal tea for preventing and improving dementia by heating the second injection at 100 to 105° C. for 30 to 40 minutes (step 5); It provides a method for manufacturing herbal tea for preventing and improving dementia, comprising a.
상기 단계 1에서, 상기 팽화미는 멥쌀 30㎏ 및 물 30㎏을 혼합하여 내부온도가 100℃인 압력가열기에서 10분 동안 가열하고, 15℃ 및 120Pa 압력 하의 진공건조기에서 건조시킨 뒤, 100~150메쉬로 분쇄하여 제조한다.In step 1, the expanded rice is mixed with 30 kg of non-glutinous rice and 30 kg of water, heated for 10 minutes in a pressure heater with an internal temperature of 100 ° C, dried in a vacuum dryer at 15 ° C and 120 Pa pressure, and then 100 to 150 mesh It is prepared by crushing
상기 단계 3에서, 상기 스테비아추출물은 스테비아 잎 10㎏을 함초수 20ℓ에 12시간 동안 침지한 후 건조하고 분쇄한 뒤, 상기 분쇄물을 초임계 추출기의 반응기에 투입하고 CO2 gas를 주입하면서 반응기를 회전시키고, 반응기 내 압력을 60기압으로 유지하면 CO2를 순환시켜 얻은 추출물을 여과하고 동결건조한 후 분말화하며 제조하되, 상기 함초수는 함초 80중량%, 매실 15중량% 및 오미자 5중량%를 혼합한 혼합물 100중량부에 구기자추출액 1,000중량부를 가하고 100~105℃에서 4~6시간 동안 가열한 후 여과하여 제조하며, 상기 구기자추출액은 구기자 100중량부에 물 300~400중량부를 가하고 95~105℃에서 1~2시간 동안 가열한 후 여과하여 제조한다.In the step 3, the stevia extract is immersed in 10 kg of stevia leaves in 20 liters of seaweed water for 12 hours, dried and pulverized, and then the pulverized product is put into a reactor of a supercritical extractor and CO 2 gas is injected into the reactor. Rotate and maintain the pressure in the reactor at 60 atmospheres, CO 2 is circulated, and the extract obtained is filtered, freeze-dried, and powdered to prepare, but the seaweed water is 80% by weight of seaweed, 15% by weight of plum, and 5% by weight of Schisandra chinensis. It is prepared by adding 1,000 parts by weight of goji berry extract to 100 parts by weight of the mixed mixture, heating at 100 to 105 ° C for 4 to 6 hours, and then filtering. It is prepared by heating at ℃ for 1 to 2 hours and then filtering.
상기 단계 4 이후에, 상기 제2 사입 100중량부에 톱니모자반추출물 1~3중량부, 마가목추출물 1~3중량부 및 금은화추출물 1~3중량부를 추가적으로 포함하되, 상기 톱니모자반추출물은 톱니모자반 100g에 2ℓ의 30%(v/v) 에탄올 수용액에 넣고 25℃에서 24시간 동안 추출하여 제조하며, 상기 마가목추출물은 마가목 100g에 2ℓ의 50%(v/v) 에탄올 수용액에 넣고 35℃에서 24시간 동안 추출하여 제조하며, 상기 금은화추출물은 금은화 100g에 2ℓ의 70%(v/v) 에탄올 수용액에 넣고 40℃에서 24시간 동안 추출하여 제조한다. After step 4, 1 to 3 parts by weight of 100 parts by weight of the second injection, 1 to 3 parts by weight of mountain ash extract, and 1 to 3 parts by weight of gold and silver flower extract are additionally included, and the 100 g of 100 g of 100 g of was added to 2 liters of 30% (v/v) ethanol aqueous solution and extracted at 25 ° C for 24 hours. The gold and silver flower extract is prepared by adding 100 g of gold and silver flowers to 2 liters of 70% (v/v) ethanol aqueous solution and extracting at 40° C. for 24 hours.
상기 단계 5 이후에, 상기 한방차 100중량부에 모링가 추출발효물 0.1~1중량부, 저령 추출발효물 0.1~1중량부 및 꾸지뽕청 0.1~1중량부를 추가적으로 포함하되, 상기 모링가 추출발효물은 모링가잎 100중량부에 80%(v/v) 에탄올 300~400중량부를 넣고 14~16시간 초음파 추출한 모링가잎 추출액 100중량부에 황국균 1~3중량부를 첨가하고 15~20℃에서 30~32시간 동안 발효시켜 제조하며, 상기 저령 추출발효물은 저령 100중량부에 70%(v/v) 에탄올 600~700중량부를 넣고 65~70℃에서 24~25시간 동안 추출한 저령 추출액 100중량부에 혼합균 1~3중량부를 첨가하고 15~20℃에서 14~15시간 동안 발효시켜 제조하며, 상기 혼합균은 유산균 60~70중량%, 홍국균 20~30중량% 및 고초균 5~15중량%를 포함하며, 상기 꾸지뽕청은 꾸지뽕 열매 100중량부에 물 800~900중량부를 가하고 100~105℃에서 4~6시간 동안 추출한 후 50~60℃에서 저온진공 농축하여 70~75Brix의 꾸지뽕 농축액을 제조한 후, 70~75℃에서 25~30분 동안 가열하여 제조힌디.After step 5, 0.1 to 1 part by weight of fermented moringa extract, 0.1 to 1 part by weight of fermented extract of moringa, and 0.1 to 1 part by weight of kkujippong extract are additionally included in 100 parts by weight of the herbal tea, and the fermented moringa extract is added. For water, add 300 to 400 parts by weight of 80% (v/v) ethanol to 100 parts by weight of Moringa leaves, add 1 to 3 parts by weight of H. It is prepared by fermentation for 30 to 32 hours, and the fermented product of the lower age extract is 100 parts by weight of the lower age extract extracted at 65 to 70 ° C for 24 to 25 hours by adding 600 to 700 parts by weight of 70% (v / v) ethanol to 100 parts by weight It is prepared by adding 1 to 3 parts by weight of mixed bacteria to the part and fermenting at 15 to 20 ° C. for 14 to 15 hours. Including, the kkujippong extract is added to 800 to 900 parts by weight of water to 100 parts by weight of kkujippong fruit, extracted at 100 to 105 ° C. for 4 to 6 hours, and then concentrated in low temperature vacuum at 50 to 60 ° C. to prepare a 70 to 75 Brix kkujippong concentrate After that, it is prepared by heating at 70 ~ 75 ℃ for 25 ~ 30 minutes.
본 발명에 따른 치매 예방 및 개선용 한방차의 제조방법은 치매 개선 효과가 우수한 장점이 있다.The manufacturing method of herbal tea for preventing and improving dementia according to the present invention has an excellent effect on improving dementia.
또한, 본 발명에 따른 치매 예방 및 개선용 한방차의 제조방법은 맛이 우수한 장점이 있다.In addition, the manufacturing method of herbal tea for preventing and improving dementia according to the present invention has an advantage of excellent taste.
이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
먼저, 본 발명에 따른 치매 예방 및 개선용 한방차의 제조방법을 설명한다.First, a method for manufacturing herbal tea for preventing and improving dementia according to the present invention will be described.
본 발명의 치매 예방 및 개선용 한방차의 제조방법은,The manufacturing method of herbal tea for preventing and improving dementia of the present invention,
팽화미 30㎏에 물 60ℓ를 가하고 증자기를 이용하여 1.2㎏/㎠, 110℃에서 30분 동안 증자한 후, 백국균(Aspergillus Kawachii) 80g을 가하고 26℃의 항온항습기에서 40시간 동안 배양하여 입국을 제조하는 단계(단계 1);After adding 60ℓ of water to 30kg of puffed rice and increasing it using a steamer at 1.2kg/cm2 at 110℃ for 30 minutes, 80g of Aspergillus Kawachii was added and cultured for 40 hours in a thermo-hygrostat at 26℃ to enter the country. manufacturing step (step 1);
상기 입국 4㎏, 물 6㎏ 및 효모 5g을 25~30℃에서 6일 동안 발효시켜 주모를 제조하는 단계(단계 2);Fermenting 4 kg of the entry, 6 kg of water, and 5 g of yeast at 25 to 30 ° C. for 6 days to prepare main hair (step 2);
상기 주모 10㎏, 상기 입국 50㎏, 물 70㎏, 참당귀 뿌리 1200g, 가시오갈피 뿌리 1000g, 은행나무 잎 1000g, 황기 800g, 두충 700g, 오미자 열매 640g, 원지 뿌리 640g, 석창포 뿌리 640g, 산사나무 열매 640g, 녹각 640g, 천궁 뿌리 500g, 프락토올리고당 500g, 용안육 열매 400g, 단삼 뿌리 390g, 감초 300g 및 스테비아추출물 10g을 22~23℃에서 6개월 동안 발효시켜 제1 사입을 얻는 단계(단계 3);10 kg of above hair, 50 kg of above seaweed, 70 kg of water, Angelica root 1200 g, Ginkgo ginseng root 1000 g, Ginkgo leaf 1000 g, Astragalus 800 g, Eucommia 700 g, Schisandra fruit 640 g, Wonji root 640 g, Iris root 640 g, Hawthorn fruit 640g, antler horn 640g, cnidium root 500g, fructo-oligosaccharide 500g, longan meat 400g, dansam root 390g, licorice 300g, and stevia extract 10g fermented at 22-23 ° C. for 6 months to obtain a first stock (step 3);
상기 제1 사입 130㎏, 팽화미 100㎏, 물 160㎏ 및 정제효소 150g을 15~16℃에서 3일 동안 발효시켜 제2 사입을 얻는 단계(단계 4); 및fermenting 130 kg of the first feed, 100 kg of puffed rice, 160 kg of water, and 150 g of purified enzyme at 15-16° C. for 3 days to obtain a second feed (step 4); and
상기 제2 사입을 100~105℃에서 30~40분 동안 가열하여 치매 예방 및 개선용 한방차를 제조하는 단계(단계 5);Preparing herbal tea for preventing and improving dementia by heating the second injection at 100 to 105 ° C. for 30 to 40 minutes (step 5);
를 포함한다.includes
상기 단계 1에서, 상기 팽화미는 멥쌀 30㎏ 및 물 30㎏을 혼합하여 내부온도가 100℃인 압력가열기에서 10분 동안 가열하고, 15℃ 및 120Pa 압력 하의 진공건조기에서 건조시킨 뒤, 100~150메쉬로 분쇄하여 제조한다.In step 1, the expanded rice is mixed with 30 kg of non-glutinous rice and 30 kg of water, heated for 10 minutes in a pressure heater with an internal temperature of 100 ° C, dried in a vacuum dryer at 15 ° C and 120 Pa pressure, and then 100 to 150 mesh It is prepared by crushing
상기 단계 3은 상기 주모 10㎏, 상기 입국 50㎏, 물 70㎏, 참당귀 뿌리 1200g, 가시오갈피 뿌리 1000g, 은행나무 잎 1000g, 황기 800g, 두충 700g, 오미자 열매 640g, 원지 뿌리 640g, 석창포 뿌리 640g, 산사나무 열매 640g, 녹각 640g, 천궁 뿌리 500g, 프락토올리고당 500g, 용안육 열매 400g, 단삼 뿌리 390g, 감초 300g 및 스테비아추출물 10g을 22~23℃에서 6개월 동안 발효시켜 제1 사입을 얻는 단계이다. In the step 3, 10 kg of the main hair, 50 kg of the inflorescence, 70 kg of water, 1200 g of angelica root, 1000 g of ginko root, 1000 g of ginkgo leaf, 800 g of Astragalus 800 g, 700 g of Eucommia, 640 g of Schizandra fruit, 640 g of root, 640 g of iris root , Hawthorn fruit 640g, deer antlers 640g, Cnidium root 500g, fructooligosaccharide 500g, Yonganyuk fruit 400g, Dansam root 390g, licorice root 300g, and stevia extract 10g are fermented at 22-23°C for 6 months to obtain the first stock. .
본 발명은, 참당귀 뿌리, 가시오갈피 뿌리, 은행나무 잎, 황기, 두충, 오미자 열매, 원지 뿌리, 석창포 뿌리, 산사나무 열매, 녹각, 천궁 뿌리, 용안육 열매, 단삼 뿌리 및 감초를 6개월 동안 발효시킴으로써 참당귀 뿌리, 가시오갈피 뿌리, 은행나무 잎, 황기, 두충, 오미자 열매, 원지 뿌리, 석창포 뿌리, 산사나무 열매, 녹각, 천궁 뿌리, 용안육 열매, 단삼 뿌리 및 감초의 약효 성분을 현저히 용출할 수 있는 장점이 있다.The present invention ferments angelica root, ginseng root, ginkgo leaf, astragalus, Eucommia, Schisandra fruit, wonji root, calamus root, hawthorn fruit, antlers, cnidium root, longan yuk fruit, sweet ginseng root, and licorice for 6 months By doing this, the medicinal ingredients of Angelica root, ginseng root, ginkgo biloba leaf, Astragalus, Eucommia, Schisandra fruit, wonji root, calamus root, hawthorn fruit, antlers, cnidium root, longan yuk fruit, sweet ginseng root and licorice can be significantly eluted. There are advantages to being
상기 당귀는 산형과에 속하는 다년생 초본식물로서, 주로 한국, 일본, 중국 등지에서 약용을 목적으로 재배되고 있다. 당귀는 그 산지에 따라 한국에서 생산되는 참당귀(Angelica gigas Nakai), 일본에서 생산되는 일당귀(Angelica acutiloba Kitagawa), 그리고 중국에서 생산되는 중국당귀(Angelica sinensis Diels)로 구분되고, 그 성분과 약리적 효과는 상이한 것으로 알려져 있다. 예로부터 당귀는 어린 순을 나물로 식용하고, 뿌리를 진통, 항암, 신장 독성경감, 간기능 개선, 당뇨성 고혈압 치료, 혈액순환 개선 등 다양한 질환에 대한 약재로 사용하고 있다. Angelica is a perennial herbaceous plant belonging to the umbel family, and is mainly cultivated for medicinal purposes in Korea, Japan, and China. Angelica gigas Nakai produced in Korea, Angelica acutiloba Kitagawa produced in Japan, and Chinese donkey produced in China (Angelica sinensis Diels) are classified according to their origin, and their components and pharmacological effects is known to be different. Since ancient times, young angelica plants have been eaten as herbs, and the root has been used as a medicine for various diseases such as pain relief, anti-cancer, reduction of kidney toxicity, improvement of liver function, treatment of diabetic hypertension, and improvement of blood circulation.
상기 가시오갈피는 두릅나무과(Araliaceae) 오갈피속(Acanthopanax)에 속하는 다년생 관목으로 러시아 및 유럽지역에서는‘Siberian ginseng’으로 더 잘 알려졌으며, 항피로, 항스트레스, 면역활성, 항우울증, 흥분완화, 항당뇨, 항암 등 다양한 약리효과가 국내외적으로 인정받고 있다.The ginseng is a perennial shrub belonging to the Araliaceae genus Acanthopanax , better known as 'Siberian ginseng' in Russia and Europe, anti-fatigue, anti-stress, immune activation, anti-depression, anti-excitement, anti-excitement Various pharmacological effects such as diabetes and anticancer are recognized domestically and internationally.
상기 은행나무 잎 (Ginkgo biloba L.)은 천식과 기관지염의 치료약으로 약 5,000년 전부터 사용하였다는 사실이 중국 약전에 기재되어 있으며 지금도 여전히 그 약효가 평가되고 있다. 근래에는 아시아와 유럽 등지에서 노인성 말초 순환장애, 뇌혈관 장애 및 천식 치료제로 널리 사용되고 있다.The fact that the ginkgo leaf ( Ginkgo biloba L. ) has been used as a treatment for asthma and bronchitis for about 5,000 years has been described in the Chinese Pharmacopoeia, and its efficacy is still being evaluated. Recently, it is widely used in Asia and Europe as a treatment for peripheral circulatory disorders, cerebrovascular disorders and asthma in the elderly.
상기 황기(Astragali Radix)는 황기(Astragalus membranaceus Bunge, 콩과 Leguminosae)의 뿌리로서 그대로 또는 주피를 제거하여 사용하는 보기제로 발한 억제, 강장, 강심, 체력증강, 피로회복 등의 목적으로 한의학에서 다용되는 약물임. 주요 기능성분으로는 cycloartane-type sapnin, isoflavonoid 및 다당체가 보고 되어져 있다.The Astragali Radix is a root of Astragalus membranaceus Bunge (leguminosae), which is used as a bogie that is used as it is or by removing the skin, which is widely used in oriental medicine for the purpose of suppressing perspiration, strengthening, strengthening, strengthening physical strength, and recovering from fatigue. is a drug. Cycloartane-type sapnin, isoflavonoid and polysaccharides have been reported as major functional components.
상기 두충(Eucommia ulmoides oliver)은 두충나무과(Eucommiaceae)에 속하는 낙엽교목 또는 이의 나무껍질을 말린 생약을 의미한다. 두충은 줄기나 잎 등이 예로부터 차로서 음용되어 왔으며, 비타민 C가 많이 함유되어 있고 부신의 기능을 높이는 작용과 함께 심장병과 당뇨병, 동맥경화 예방에 효과가 있다. 그 줄기나 잎 등이 옛부터 고혈압, 스트레스, 관절염, 숙취 등의 각종 질병에 유용한 생약으로서 음용되어 왔을 뿐만 아니라, 최근 들어 임상적인 실험을 통해 두충에 함유된 여러 성분들의 약리학적 메카니즘이 점차 밝혀짐에 따라 그 가치가 재인식되고 있고, 건강차로서 많이 음용되고 있다.The Eucommia ulmoides oliver refers to a deciduous tree belonging to Eucommiaceae or a dried crude drug of its bark. Eucommia stems and leaves have been drunk as tea since ancient times, and contain a lot of vitamin C, and are effective in preventing heart disease, diabetes, and arteriosclerosis with the action of increasing adrenal function. Its stems and leaves have been consumed as herbal medicines useful for various diseases such as high blood pressure, stress, arthritis, and hangovers since ancient times, and recently, clinical experiments have gradually revealed the pharmacological mechanisms of various components contained in Eucommia. Accordingly, its value is being recognized again, and it is widely consumed as a health tea.
상기 오미자(Schizandra chinensis)는 목련과 식물의 열매로서 한약재료, 차 또는 하절기의 화채재료 및 그 색소를 이용한 녹말다식과 오미자주로 가공, 이용되고 있다. 오미자에는 다량의 유기산과 안토시아닌(anthocyanin) 색소가 함유되어 있고, 노화 억제 활성, 면역조절 작용 및 항균활성 등이 알려져 있다.The Schizandra chinensis ( Schizandra chinensis ) is a fruit of a magnolia family plant, and is processed and used as herbal medicine material, tea or summer flower material, and starchy food and Schizandra chinensis using its pigment. Schisandra chinensis contains a large amount of organic acids and anthocyanin pigments, and is known to have anti-aging activity, immunomodulatory activity, and antibacterial activity.
상기 원지(Polygala tenuifolia)는 무환자나무목에 속하는 식물로, 한방에서는 뿌리부분을 약용으로 사용하며, 진정작용, 최면작용, 강심작용, 가래삭임작용, 용혈작용 등의 효능이 있다. The base paper (Polygala tenuifolia) is a plant belonging to the tree without patients.
상기 석창포는 천남성과(Araceae)에 속하는 다년생 초본으로 한국, 중국, 일본 등지에서 자생하고 있으며, 한국에서는 중부와 남부지방에서 자생한다. 석창포는 산골짜기에서 자라며 뿌리줄기는 옆으로 길게 자라고 지상에 있는 줄기와 더불어 독특한 향기가 나는 식물이다. 석창포는 연못가나 도랑가에서 자라는 일반 창포보다 잎이 보다 좁고 길이가 짧으며 뿌리가 가는 특징이 있다. 또한 석창포의 다른 이름으로 수검초, 요구, 창본, 창양, 창초, 창포, 구절창포 등이 있다.The seokchangpo is a perennial herb belonging to Araceae and is native to Korea, China, and Japan, and is native to the central and southern regions of Korea. Seokchangpo is a plant that grows in mountain valleys and has a rhizome that grows sideways and has a unique scent along with the stem on the ground. Seokchangpo is characterized by narrower leaves, shorter length, and thin roots than general irises that grow along ponds or ditches. In addition, other names for seokchangpo include sugeomcho, demand, changbon, changyang, changcho, iris, and gujeolchangpo.
상기 산사나무(Crataegus pinnatifida Bunge)는 쌍떡잎식물 장미목 장미과의 낙엽활엽 소교목이다. 높이 3~6 m로 나무 껍질은 잿빛이고 가지에 가시가 있고 잎은 어긋나고 달걀 모양에 가까우며 길이 6~8 cm, 나비 5~6 cm로 가장자리가 깃처럼 갈라지고 밑부분은 더욱 깊게 갈라진다. 양면 맥 위에 털이 나고 가장자리에 불규칙한 톱니가 있으며 잎자루는 길이 2~6 cm이며 꽃은 5월에 흰색으로 피고 산방꽃차례에 달리며 꽃잎은 둥글며 꽃받침조각과 더불어 5개씩이다. 수술은 20개이며 암술대는 3-5개, 꽃밥은 붉은색이며 열매는 이과로서 둥글며 흰 반점이 있으며 지름 약 1.5 cm이고 9-10월에 붉은빛으로 익는다. 한국·중국·시베리아 등지에 분포한다.The hawthorn (Crataegus pinnatifida Bunge) is a deciduous broad-leaved small tree of the dicotyledonous rose order Rosaceae. The tree is 3-6 m high, the bark is grayish, the branches have thorns, the leaves are alternate, close to egg shape, 6-8 cm long, 5-6 cm wide, the edges are split like feathers, and the lower part is deeply split. Hairs grow on both veins, irregular sawtooth on the edge, petiole is 2-6 cm long, white flowers bloom in May, hang on corymbs, petals are round, 5 each with calyx pieces. There are 20 stamens, 3-5 styles, anthers are red, and fruits are pomes, round with white spots, about 1.5 cm in diameter, and ripen in red in September-October. Distributed in Korea, China, Siberia, etc.
상기 녹각은 녹용의 채취시기가 늦어져서 골화(Ossification)가 현저하게 진행된 것을 말한다.The antler means that ossification has progressed remarkably because the harvesting time of the antler has been delayed.
상기 천궁(Cnidii Rhizoma)은 토천궁(Ligusticum chuanxiong Hort.) 또는 일천궁(Cnidium officinale Makino)의 뿌리줄기를 이용하는 약용자원식물로서 산형과(Umbelliferae)에 속하는 다년생 초본이다. 주요 성분으로는 니딜라이드(cnidilide), 리구스틸라이드(ligustilide), 부틸이데네프탈리드(butylidenephthalide), 센큐노라이드(senkyunolide) 등의 정유성분, 페루릭산(ferulic acid), 클로제닉산(chlorogenic acid) 등의 페놀성 물질 등이 알려져 있다. 천궁은 진경작용, 진정작용, 혈압강하작용, 혈관확장작용, 항균작용, 항진균작용 등의 약리작용이 알려져 있으며, 한방에서는 두통, 불임, 월경불순, 강장, 냉증, 빈혈 등의 질환에 사용하고 있다.The Cnidii Rhizoma is a medicinal resource plant using the rhizome of Ligusticum chuanxiong Hort. or Cnidium officinale Makino, and is a perennial herb belonging to the family Umbelliferae . The main components include essential oil components such as cnidilide, ligustilide, butylidenephthalide, and senkyunolide, ferulic acid, and chlorogenic acid. acid) and the like are known. Cnidium is known for its pharmacological actions such as antispasmodic action, sedation action, blood pressure lowering action, vasodilation action, antibacterial action, and antifungal action. .
상기 프락토올리고당은 설탕과 매우 유사한 감미질을 가지고 있으며 감미도가 설탕의 60%이고, 건강기능성까지 포함하고 있어 설탕 대체제로 주목 받고 있다. 프락토올리고당은 설탕을 기질로 하여 과당 전이효소를 사용하여 설탕에 과당이 1 내지 3개 결합된 성분의 혼합물을 말한다. 프락토올리고당은 장내 유익균 증식 및 유해균 억제에 도움을 주고, 배변활동 원활에 도움을 주는 정장작용의 효과가 있다.The fructooligosaccharide has a very similar sweetness to sugar, has a sweetness of 60% of sugar, and has health functionalities, so it is attracting attention as a sugar substitute. Fructooligosaccharide refers to a mixture of components in which 1 to 3 fructose are bonded to sugar using fructose transferase as a substrate. Fructooligosaccharides help to proliferate beneficial bacteria in the intestine and inhibit harmful bacteria, and have an effect on intestinal function that helps smooth bowel movements.
상기 용안육(Lonaganae Arillus)은 무환자나무과(Sapindaceae)의 상록교목이고 열매의 용안의 과육을 말한다. 대한약전에서 용안육은, 용안의 헛씨껍질로 세로로 파열된 불규칙한 박편으로서 보통 여러 개가 끈끈하게 붙어 있고, 길이 2~4 cm, 너비 1~2 cm, 두께 2~4 mm이며, 바깥면은 진한 적갈색~흑갈색으로 반투명하여 한 면은 주름이 지어 고르지 않고 다른 면은 윤기가 있으며 세로 주름이 있고, 질은 부드럽고 점착성이며, 약간 특유한 냄새가 있고 맛은 달다고 정의되어 있다.The longan yuk ( Lonaganae Arillus ) is an evergreen tree of Sapindaceae and refers to the flesh of the longan fruit. In the Korean Pharmacopoeia, Yongan yuk is a longitudinally ruptured irregular slice of longan husk, usually several sticking together, 2 to 4 cm long, 1 to 2 cm wide, and 2 to 4 mm thick, with a dark reddish brown outer surface. It is defined as ~blackish-brown translucent, wrinkled and uneven on one side, shiny and vertically wrinkled on the other side, soft and viscous in quality, slightly characteristic odor, and sweet in taste.
상기 단삼 (Salvia miltiorrhiza BUNGE)은 한방에서 예로부터 널리 사용된 약재로 꿀풀과 (Labiatae)에 속하는 쌍떡잎식물 통화식물목의 여러해살이풀로 원산지는 중국이다. 단삼은 수염뿌리를 제거하고 햇볕에 말린 뿌리를 약용으로 하며 11월 상순부터 다음해 3월 상순까지 채취하는데 11월 상순에 캐낸 것이 가장 좋은 것으로 알려져 있다. 단삼의 뿌리에 함유된 성분으로는 탄시논 I (tanshinone I), 탄시논 ⅡA (tanshinone ⅡA), 탄시논 ⅡB (tanshinone ⅡB), 디히드로탄시논 (dihydrotanshinone), 메틸탄시노네이트 (methyl tanshinonate), 메틸렌 탄시퀴논 (methylene tanshinquinone), 베타-시토스테롤 (betasitosterol), 히드록시탄시논(hydroxytanshinone), 네오탄시논 (neotanshinone) AㆍBㆍC, 살비올 (salviol), 이소탄시논 I (isotanshinone I), 이소탄시논 Ⅱ (isotanshinone Ⅱ), 이소크립토탄시논(isocryptotanshinone), 밀티론 (miltirone), 탄시놀 I (tanshinol I), 탄시놀 Ⅱ (tanshinol Ⅱ) 및 비타민 E (vitamin E) 등이 보고되고 있다.The Dansam (Salvia miltiorrhiza BUNGE) is a medicinal herb widely used in oriental medicine from ancient times, and is a perennial plant belonging to the Lamiaceae (Labiatae), a dicotyledonous plant, and its origin is China. Dansam removes the beard roots and uses the sun-dried roots for medicinal purposes. It is collected from early November to early March of the following year. Components contained in the root of Danshen include tanshinone I, tanshinone ⅡA, tanshinone IIB, dihydrotanshinone, and methyl tanshinonate. , methylene tanshinquinone, beta-sitosterol, hydroxytanshinone, neotanshinone A B C, salviol, isotansinone I ( isotanshinone I), isotanshinone II, isocryptotanshinone, miltirone, tanshinol I, tanshinol II and vitamin E ) have been reported.
상기 감초 (Glycyrrhiza uralensis)는 콩과에 속하는 여러해살이풀로서 중국 북부, 시베리아, 이태리 남부, 만주, 몽고 등지에 자생 또는 재배된다. 감초는 모든 한약처방에서 독성을 줄이는 성분으로 들어가고 진해제로 쓰이는 약초 중 하나이며, 유럽에서는 담배나 껌 그리고 사탕 등에 단맛을 내기 위해 사용하기도 한다. 최근 연구 결과에 따르면 감초는 신장의 산화적 손상을 완화시키며, 카드뮴에 의해 손상되는 간세포를 보호하는 효과도 있는 것으로 확인된 바 있다.The licorice ( Glycyrrhiza uralensis ) is a perennial plant belonging to the leguminous family and is native to or cultivated in northern China, Siberia, southern Italy, Manchuria, Mongolia and the like. Licorice is one of the herbs used as an antitussive and enters as a component to reduce toxicity in all herbal prescriptions. In Europe, it is also used to sweeten cigarettes, gum, and candy. According to recent research results, it has been confirmed that licorice alleviates oxidative damage in the kidneys and has the effect of protecting liver cells from damage by cadmium.
상기 스테비아는 국화과에 속하는 다년생 숙근초로서, 스테비아 잎에는 주요한 감미성분으로 스테비오사이드(stevioside)를 전초 무게 대비 6~7%로 함유하고 있다. 상기 스테비오사이드는 감미도가 설탕의 250배이며, 비발암성 혹은 무칼로리의 당 대체 감미료로서 활용되고 있다.The stevia is a perennial root plant belonging to the Asteraceae family, and the stevia leaf contains 6 to 7% of stevioside as a main sweetening component compared to the weight of the outpost. The sweetness of stevioside is 250 times that of sugar, and is used as a non-carcinogenic or non-caloric substitute sweetener.
상기 스테비아추출물은 스테비아 잎 10㎏을 함초수 20ℓ에 12시간 동안 침지한 후 건조하고 분쇄한 뒤, 상기 분쇄물을 초임계 추출기의 반응기에 투입하고 CO2 gas를 주입하면서 반응기를 회전시키고, 반응기 내 압력을 60기압으로 유지하면 CO2를 순환시켜 얻은 추출물을 여과하고 동결건조한 후 분말화한다.The stevia extract was immersed in 10 kg of stevia leaves in 20 L of seaweed water for 12 hours, dried and pulverized, and then the pulverized product was put into a reactor of a supercritical extractor, and the reactor was rotated while injecting CO 2 gas, When the pressure is maintained at 60 atm, the extract obtained by circulating CO 2 is filtered, freeze-dried, and then powdered.
상기 함초수는 함초 80중량%, 매실 15중량% 및 오미자 5중량%를 혼합한 혼합물 100중량부에 구기자추출액 1,000중량부를 가하고 100~105℃에서 4~6시간 동안 가열한 후 여과하여 제조한다. The seaweed water is prepared by adding 1,000 parts by weight of goji berry extract to 100 parts by weight of a mixture of 80% by weight of seaweed, 15% by weight of plum, and 5% by weight of Schisandra chinensis, heated at 100 to 105 ° C. for 4 to 6 hours, and then filtered.
상기 구기자추출액은 구기자 100중량부에 물 300~400중량부를 가하고 95~105℃에서 1~2시간 동안 가열한 후 여과하여 제조하였다.The goji berry extract was prepared by adding 300 to 400 parts by weight of water to 100 parts by weight of goji berry, heating at 95 to 105 ° C. for 1 to 2 hours, and then filtering.
상기 단계 4는 상기 제1 사입 130㎏, 팽화미 100㎏, 물 160㎏ 및 정제효소 150g을 15~16℃에서 3일 동안 발효시켜 제2 사입을 얻는 단계이다. Step 4 is a step of obtaining a second feed by fermenting 130 kg of the first feed, 100 kg of puffed rice, 160 kg of water, and 150 g of purified enzyme at 15-16 ° C for 3 days.
상기 팽화미는 단계 1에서 제조한 팽화미를 사용한다.The expanded rice prepared in step 1 is used as the expanded rice.
상기 단계 4 이후에, 상기 제2 사입 100중량부에 톱니모자반추출물 1~3중량부, 마가목추출물 1~3중량부 및 금은화추출물 1~3중량부를 추가적으로 포함할 수 있다.After the step 4, 1 to 3 parts by weight of a sawtooth cap extract, 1 to 3 parts by weight of a rowan extract, and 1 to 3 parts by weight of a silver flower extract may be additionally included in 100 parts by weight of the second injection.
상기 제2 사입에 톱니모자반추출물, 마가목추출물 및 금은화추출물을 추가적으로 포함함으로써 치매 개선효과를 더욱 향상시킬 수 있는 장점이 있다.There is an advantage in that the effect of improving dementia can be further improved by additionally including a sawtooth capricorn extract, a rowan extract, and a gold silver flower extract in the second injection.
상기 톱니모자반추출물은 톱니모자반 100g에 2ℓ의 30%(v/v) 에탄올 수용액에 넣고 25℃에서 24시간 동안 추출하여 제조한다.The cap and cap extract is prepared by putting 100 g of cap and cap in 2 liters of 30% (v/v) ethanol aqueous solution and extracting at 25° C. for 24 hours.
상기 톱니모자반(Sargassum serratifolium)은 조간대에서 점심대에 걸쳐 생육하는 식물로서 1~4m인 다년생 대형 갈조류이다. 뿌리는 지름 4~5cm로 원뿔상이고, 고무와도 같으며 나이테가 있고, 줄기는 원주상으로 짧고 다수의 중심가지로 나뉘며 편압되어 있다. 또한 줄기의 양 가장자리가 얇고, 세로로 중륵처럼 한쪽으로 융기하며, 가장자리에서 짧은 가지를 내고 있으며 줄기잎은 기부로 향하여 있고, 가장자리에 2중으로 된 톱니가 있으며, 기포는 둥근 모양에 가까우며 그 꼭대기에 관엽 또는 가시 모양의 돌기가 있다. 특히 우리나라의 남해안과 제주에 생육하는 것으로 알려져 있으며, 지질강하, 혈압강하, 방사성 동위원소 배출작용에 대한 기능을 가지고 있는 것으로 알려져 있다.The sawtooth cap ( Sargassum serratifolium ) is a plant that grows from the intertidal zone to the lunch zone and is a perennial large brown algae of 1 to 4 m. The root is 4-5cm in diameter, conical, like rubber, with annual growth rings, and the stem is short, circumferential, divided into many central branches, and flattened. In addition, both edges of the stem are thin, vertically raised on one side like a midrib, and short branches are produced at the edge. There are leaves or thorn-like projections. In particular, it is known to grow in the southern coast of Korea and Jeju, and is known to have functions for lowering lipids, lowering blood pressure, and releasing radioactive isotopes.
상기 마가목추출물은 마가목 100g에 2ℓ의 50%(v/v) 에탄올 수용액에 넣고 35℃에서 24시간 동안 추출하여 제조한다.The rowan extract is prepared by adding 100 g of rowan tree to 2 liters of 50% (v/v) ethanol aqueous solution and extracting at 35° C. for 24 hours.
상기 마가목(Sorbus commixta)은 장미과 마가목속에 속하는 갈잎작은키나무로 해발 500m-1000m 산지에서 잘 자라며 일본이나, 중국, 유럽과 미국 등지에도 분포하는 나무이다. 약명은 한자명으로 정공등 이라고 하여 가래, 기침, 혈압강하, 이뇨작용에 효능이 있는 것으로 알려져 있으며, 한방에서 마가목의 수피는 마아피라 하여 기관지염, 류마티스 관절염, 중풍, 위염, 보신, 골통에 사용하며, 열매는 차로 이용하거나 생식할 수 있다.The rowan tree (Sorbus commixta) is a deciduous tree belonging to the genus Rosaceae Rowan, which grows well in mountains at an altitude of 500m-1000m and is a tree distributed in Japan, China, Europe and the United States. The drug name is known as Jeonggong in Chinese characters, and is known to be effective in phlegm, cough, lowering blood pressure, and diuretic action. The fruit can be used as a tea or eaten raw.
상기 금은화추출물은 금은화 100g에 2ℓ의 70%(v/v) 에탄올 수용액에 넣고 40℃에서 24시간 동안 추출하여 제조한다.The gold and silver flower extract is prepared by putting 100 g of gold and silver flowers in 2 liters of 70% (v/v) ethanol aqueous solution and extracting at 40° C. for 24 hours.
상기 금은화는(Lonicerae flos)는 인동과(Caprifoliacear)식물인 덩굴성 관목 인동덩굴(Lonicera japonica)의 꽃봉오리로 한방이나 민간에서는 이뇨, 건위, 관절염, 화농성 피부염, 기관지염에 사용하고 있다. 금은화의 성분 연구로는 탄닌(tannin), 이노시톨(inositol), 스테롤(sterol), 클로로제닉산(chlorogenic aicd), 이소콜로로제닉산(isochlorogenic acid), 아피게닌(apigenin), 퀘르세틴(quercetin) 등이 알려져 있다. 금은화의 활성에 대한 보고로는 항염증효과, HIV-1 RT에 대한 선택적 억제효과, 포스포리파아제 A2의 불활성화효과, 주부습진(Honeysukcle contact dermatitis) 치료, 소아 기관지폐렴의 치료효과, 혈소판 활성 및 내피세포손상억제효과, 바이러스성 심근염 치료효과, 변형된 세포 매개 면역효과 등이 알려져 있다.The gold silver flower ( Lonicerae flos ) is a flower bud of Lonicera japonica, a creeping shrub Lonicera japonica , which is a Caprifoliacear plant, and is used in oriental medicine or privately for diuresis, stomachache, arthritis, purulent dermatitis, and bronchitis. Research on the components of gold and silver flowers includes tannin, inositol, sterol, chlorogenic acid, isochlorogenic acid, apigenin, quercetin, etc. this is known Reports on the activity of gold silver flowers include anti-inflammatory effect, selective inhibitory effect on HIV-1 RT, inactivation effect of phospholipase A2, treatment of honeysukcle contact dermatitis, treatment of pediatric bronchopneumonia, platelet activity and Endothelial cell damage inhibitory effect, viral myocarditis treatment effect, modified cell-mediated immunity effect, etc. are known.
상기 단계 5는 상기 제2 사입을 100~105℃에서 30~40분 동안 가열하여 한방차를 제조하는 단계이다. Step 5 is a step of preparing herbal tea by heating the second injection at 100 to 105 ° C. for 30 to 40 minutes.
상기 제2 사입을 100~105℃에서 30~40분 동안 가열함으로써 알콜 성분을 증발시키고 액상의 한방차를 수득할 수 있다.By heating the second injection at 100 to 105 ° C. for 30 to 40 minutes, the alcohol component can be evaporated and liquid herbal tea can be obtained.
상기 단계 5 이후에, 상기 한방차 100중량부에 모링가 추출발효물 0.1~1중량부, 저령 추출발효물 0.1~1중량부 및 꾸지뽕청 0.1~1중량부를 추가적으로 포함할 수 있다.After the step 5, 0.1 to 1 part by weight of fermented moringa extract, 0.1 to 1 part by weight of fermented extract of moringa, and 0.1 to 1 part by weight of kkujippong extract may be additionally included in 100 parts by weight of the herbal tea.
상기 한방차에 모링가 추출발효물, 저령 추출발효물 및 꾸지뽕청을 추가적으로 포함함으로써 한방차의 맛을 더욱 향상시킬 수 있는 장점이 있다.There is an advantage in that the taste of the herbal tea can be further improved by additionally including the fermented Moringa extract, the fermented extract, and the fermented kkujippong extract in the herbal tea.
상기 모링가 추출발효물은 모링가잎 100중량부에 80%(v/v) 에탄올 300~400중량부를 넣고 14~16시간 초음파 추출한 모링가잎 추출액 100중량부에 황국균 1~3중량부를 첨가하고 15~20℃에서 30~32시간 동안 발효시켜 제조한다. The fermented Moringa extract is added with 300 to 400 parts by weight of 80% (v / v) ethanol to 100 parts by weight of Moringa leaves, and 1 to 3 parts by weight of H. It is prepared by fermentation at 15-20℃ for 30-32 hours.
상기 모링가는 원산지가 인도인 소목이지만, 전세계 어디에서나 재배되고 모링가 나무가 널리 이용되는 많은 지역들에서 귀화되어 야생된다. 모링가과에 속하는 13 종의 모링가 나무가 있으며, 모링가 올레이페라(Moringa oleifera)가 가장 널리 알려져 있다. 모링가 올레이페라는 우산과 같이 펼쳐진 4 내지 8 미터 높이의 관목이다. 30 내지 70 cm 길이의 잎들은 낙엽성이며, 꽃들은 흰색이고 향기가 진하며, 열매는 녹색이고 혁질성 및 현수성의 긴 삼각형상의 긴 깍지로 길이는 30 내지 40 cm에 이르는 특징을 가지며, 인도 북서부 히말라야 산기슭에 자생하고, 열대 전 지역에서 재배하는 다목적 수종의 일종이다. 모링가(Moringa oleifera)는 동남아시아 등에서 자생하는 식물로서 다량의 영양분을 함유하고 있어 기적의 식물로 불리고 있으며, 항당뇨, 항암, 항알러지 등 다양한 효능이 있는 것으로 알려져 있다.Although Moringa is a small tree native to India, it is cultivated anywhere in the world and is naturalized and wild in many areas where Moringa trees are widely used. There are 13 species of Moringa trees belonging to the Moringa family, with Moringa oleifera being the most widely known. Moringa oleifera is a shrub 4 to 8 meters tall that spreads like an umbrella. The leaves are deciduous with a length of 30 to 70 cm, the flowers are white and fragrant, the fruits are green, and the length is 30 to 40 cm with long leathery and hanging triangular pods. It is a kind of multi-purpose tree native to the foot of a mountain and cultivated in all tropical regions. Moringa (Moringa oleifera) is a plant native to Southeast Asia, etc., and is called a miracle plant because it contains a large amount of nutrients, and is known to have various effects such as anti-diabetic, anti-cancer, and anti-allergy.
상기 황국균은 우리 전통메주 제조시 일부 자생균으로 부착되어온 균들 중의 일종이지만 일찍부터 일본에서 된장, 간장, 청주 등의 고지제조에 순수분리해서 사용해왔다.The Hwanggukgyun is a kind of bacteria that has been attached to some of the native bacteria in the production of Korean traditional meju, but has been used as a pure separation in the production of soybean paste, soy sauce, and rice wine in Japan.
상기 저령 추출발효물은 저령 100중량부에 70%(v/v) 에탄올 600~700중량부를 넣고 65~70℃에서 24~25시간 동안 추출한 저령 추출액 100중량부에 혼합균 1~3중량부를 첨가하고 15~20℃에서 14~15시간 동안 발효시켜 제조한다. The jeoryeong extract fermented product is added to 100 parts by weight of 70% (v / v) ethanol, 600 to 700 parts by weight of 70% (v / v) ethanol, and 1 to 3 parts by weight of mixed bacteria added to 100 parts by weight of jeoryeong extract extracted at 65 to 70 ° C for 24 to 25 hours. and fermented for 14 to 15 hours at 15 to 20 ° C.
상기 혼합균은 유산균 60~70중량%, 홍국균 20~30중량% 및 고초균 5~15중량%를 포함한다. The mixed bacteria include 60 to 70% by weight of lactic acid bacteria, 20 to 30% by weight of Honggukgyun, and 5 to 15% by weight of Bacillus subtilis.
상기 저령(Polyporus umbellatus)은 주령, 시령, 저시령, 지오도, 희령, 가저시 등의 이명으로도 불리며, 분류상 담자균류 민주름버섯목 구멍장이버섯과에 속하는 버섯으로, 가을에 활엽수림 내의 특히 오리나무, 참나무, 단풍나무나 떡갈나무 등의 산뿌리에 기생하며 그 성미는 달고 쓰다. 주로 한국, 일본, 유럽, 중국, 미국 등에 분포하며, 자루는 밑동에서 몇 번 갈라지며 갓은 각 가지의 끝에 핀다. 높이는 10~20cm, 지름은 10~30cm이다. 균핵은 불규칙한 괴상으로 생강과 비슷한 것이 많고 표면은 특이한 형태를 보이며 황백색 또는 족제비색이다. 마치 돼지 변과 비슷하여 ‘저령’이란 명칭이 붙었다. 자실체는 복잡하게 가지친 자루와 갓으로 된다. 불규칙한 긴덩어리이거나 원형에 가까운 덩어리로 크기는 고르지 않으며 긴 것은 대개 굽어 있거나 생강처럼 갈라지며 길이 5~25cm이다. 표면은 흑색이거나 흑갈색으로 쭈그러져 있거나 혹은 혹모야의 돌기가 있다. 가볍고 질기며 단면은 유백색이거나 황백색을 띤다. 저령은 수분대사를 원활하게 하는 효능이 있으며, 소변을 잘 보지 못하거나 온몸에 부종이 있을 때 이용하고 임신중에 소변을 잘 보지 못하고 다리가 붓는 증상, 소화기능이 약하여 속이 차고 설사를 하는 증상에 좋다.The low age ( Polyporus umbellatus ) is also called by names such as Ju-ryeong, Shi-ryeong, Jeo-si-ryeong, Geo-do, Huiryeong, Gajeosi, etc., and is classified as a mushroom belonging to the basidiomycete Minoreum Mushroom Tree Holey Mushroom Family, especially in broad-leaved forests in autumn It is parasitic on the roots of alder, oak, maple and oak trees, and is sweet and bitter. It is mainly distributed in Korea, Japan, Europe, China, and the United States, and the stem is split several times at the base, and the cap blooms at the end of each branch. The height is 10-20 cm, and the diameter is 10-30 cm. The sclerotium is an irregular mass, and there are many similar to ginger, and the surface shows a peculiar shape and is yellowish white or weasel color. It resembles pig stool, hence the name 'Jeoryeong'. The fruiting body becomes a complicatedly branched stalk and cap. Irregular long lumps or lumps close to round, the size is uneven, and the long ones are usually bent or cracked like ginger, 5 to 25 cm long. The surface is black, wrinkled in black brown, or has bumpy projections. It is light and tough, and the cross section is milky white or yellowish white. Jeoryeong has the effect of facilitating water metabolism, and is used when you cannot urinate well or have swelling throughout the body. .
상기 유산균은 락토바실러스 델브루에키(Lactobacillus delbrueckii), 락토바실러스 불가리쿠스(Lactobacillus bulgaricus), 락토바실러스 카세이(Lactobacillus casei), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 아시도필러스(Lactobacillus acidophilus), 페디오코커스 펜토사세우스(Pediococcus pentosaceus), 페디오코커스 세레비세(Pediococcus cerevisiae), 락토코커스 락티스(Lactococcus lactis), 레코노스톡 시트레움(Leuconostoc citreum), 레코노스톡 메센테로이드(Leuconostoc mesenteroides), 비피도박테리움 비피둠(Bifidobacterium bifidum) 및 락토바실러스 람노수스(Lactobacillus rhamnosus)로 이루어진 군에서 선택된 어느 하나를 사용할 수 있다.The lactic acid bacteria are Lactobacillus delbrueckii , Lactobacillus bulgaricus , Lactobacillus casei , Lactobacillus brevis , Lactobacillus acidophilus , Pedi Ococus pentosaceus ( Pediococcus pentosaceus ), Pediococcus cerevisiae ( Pediococcus cerevisiae ), Lactococcus lactis ( Lactococcus lactis ), Leuconostoc citreum ( Leuconostoc citreum ), Leconostoc mesenteroids ( Leuconostoc mesenteroides ), Any one selected from the group consisting of Bifidobacterium bifidum and Lactobacillus rhamnosus may be used.
상기 홍국균은 자낭균문 모나스커스(Monascus)속에 속하는 붉은색의 사상균으로서, 쌀 등과 같은 곡류를 발효시키는 과정에서 각종 유익한 대사산물로 진한 빨간색의 색소 및 모나콜린 K 등을 생산한다. 이 균은 중국을 중심으로 동아시아의 여러 지역에서 천연의 식품 착색제나 가공품 및 소화 촉진과 혈류 개선의 소재로서 오랫동안 사용되어 왔다. 홍국균이 생성하는 2차 대사산물인 메비놀린은 콜레스테롤 생합성효소인 HMG-CoA(3-hydroxy-methyl-3-glutaryl-coenzyme) 환원효소를 강력하게 저해하여 혈중지질 농도를 감소시키고 콜레스테롤 합성을 억제하거나 항진균, 혈당상승의 억제, 혈압조절, 항비만, 항암 등과 같은 각종 기능성을 가진다. 또한, 홍국균은 적색계 색소(rubropuntain, monascorubin)와 황색계 색소(monascin, ankaflavin), 자색계 색소(rubropunctamine, monascorubramine) 등을 생성하며, 이와 같은 색소물질은 항균 및 항암효과가 있다.The honggukgyun is a red filamentous fungus belonging to the genus Monascus, and produces dark red pigments and monacolin K as various useful metabolites in the process of fermenting grains such as rice. This fungus has been used for a long time in various parts of East Asia, mainly in China, as a natural food coloring agent, processed product, and material for promoting digestion and improving blood flow. Mebinolin, a secondary metabolite produced by Honggukgyun, strongly inhibits HMG-CoA (3-hydroxy-methyl-3-glutaryl-coenzyme) reductase, a cholesterol biosynthetic enzyme, to reduce blood lipid concentration and inhibit cholesterol synthesis or It has various functions such as antifungal, inhibition of blood sugar rise, blood pressure control, anti-obesity, and anti-cancer. In addition, honggukgyun produces red pigments (rubropuntain, monascorubin), yellow pigments (monascin, ankaflavin), purple pigments (rubropunctamine, monascorubramine), and the like, and these pigment substances have antibacterial and anticancer effects.
상기 홍국균은 모나스커스 필로서스(Monascus pilosus), 모나스커스 러버(Monascus ruber), 모나스커스 퍼프레우스(Monascus purpureus), 모나스커스 카올리앙(Monascus kaoliang), 모나스커스 바리케리(Monascus barykery) 및 모나스커스 안카(Monascus anka)로 이루어진 군에서 선택된 어느 하나를 사용할 수 있다.The honggukgyun is Monascus pilosus, Monascus rubber, Monascus ruber , Monascus purpureus , Monascus kaoliang , Monascus barykery and Monas Any one selected from the group consisting of Monascus anka may be used.
상기 고초균은 바실러스 섭틸리스(B. subtilis), 바실러스 리크네포르미스(B. lichneformis), 바실러스 메가테리움(B. megaterium), 바실러스 아밀로리퀘파시엔스(B. amyloliquefaciens), 바실러스 낫토(B. natto), 바실러스 안스라시스(B.antharcis), 바실러스렌투스(B.lentus), 바실러스 퍼미러스(B.pumilus), 바실러스 더링지엔시스(B.thuringiensis), 바실러스 알베이(B.alvei), 바실러스 아조토픽산스(B.azotofixans), 바실러스 매세란스(B.macerans), 바실러스 포리믹사(B.polymyxa), 바실러스 파필리에(B.popilliae), 바실러스 코아글란스(B.coagulans), 바실러스 스테아로더모필러스(B.stearothermophilus), 바실러스 파스퇴리(B.pasteurii), 바실러스 패리커스(B.sphaericus) 및 바실러스 패스티디오서스(B.fastidiosus)로 이루어진 군에서 선택된 어느 하나를 사용할 수 있다.The Bacillus subtilis is Bacillus subtilis ( B. subtilis ), Bacillus lichneformis ( B. lichneformis ), Bacillus megaterium ( B. megaterium ), Bacillus amyloliquefaciens ( B. amyloliquefaciens ), Bacillus natto ( B. natto ), Bacillus anthracis ( B.antharcis ), Bacillus lentus ( B.lentus ), Bacillus furmirus ( B.pumilus ), Bacillus thelingsiensis ( B.thuringiensis ), Bacillus albei ( B.alvei) ), Bacillus azotopic Sans ( B.azotofixans ), Bacillus Macerans ( B.macerans ), Bacillus polymyxa ( B.polymyxa ), Bacillus papilliae ( B.popilliae ), Bacillus coagulans ( B.coagulans ), Bacillus Stearodermophilus ( B.stearothermophilus ), Bacillus Pasteurii ( B.pasteurii ), Bacillus paricus ( B.sphaericus ) and Bacillus Pastidiosus ( B.fastidiosus ) Any one selected from the group consisting of can be used.
상기 꾸지뽕청은 꾸지뽕 열매 100중량부에 물 800~900중량부를 가하고 100~105℃에서 4~6시간 동안 추출한 후 50~60℃에서 저온진공 농축하여 70~75Brix의 꾸지뽕 농축액을 제조한 후, 70~75℃에서 25~30분 동안 가열하여 제조한다.The kkujippong cheong is added to 800 to 900 parts by weight of water to 100 parts by weight of kkujippong fruit, extracted at 100 to 105 ° C for 4 to 6 hours, and then concentrated in low temperature vacuum at 50 to 60 ° C. After preparing a concentrate of 70 to 75 Brix, 70 It is prepared by heating at ~75°C for 25-30 minutes.
상기 꾸지뽕나무는 뽕나무과의 일부로 꾸지뽕나무에서 자생하는 열매는 음료, 쨈, 고추장 등과 같은 많은 상품으로 사용되고 있고, 꾸지뽕 열매는 가바, 루틴, 플라보노이드, 모르틴 아사파라간산 등 약리적인 물질을 포함하고 있는데, 특히 가바는 신경전달 물질로 불안, 우울, 불면증, 기억력 개선에도 좋은 효과를 볼 수 있으며, 루틴 성분은 모세혈관을 튼튼하게 해주어 당뇨나 혈압에도 좋은 효과가 있는 것으로 알려져 있다.The kuji mulberry tree is a part of the Morus family, and the fruit that grows naturally in the cudra mulberry tree is used in many products such as beverages, jam, red pepper paste, etc., and the cudra mulberry fruit contains pharmacological substances such as GABA, rutin, flavonoids, mortin asaparaganic acid, In particular, GABA is a neurotransmitter that can have good effects on anxiety, depression, insomnia, and memory improvement, and rutin strengthens capillaries and is known to have a good effect on diabetes and blood pressure.
본 발명에 따른 치매 예방 및 개선용 한방차의 제조방법은 치매 개선 효과가 우수한 장점이 있다. The manufacturing method of herbal tea for preventing and improving dementia according to the present invention has an excellent effect on improving dementia.
또한, 본 발명에 따른 치매 예방 및 개선용 한방차의 제조방법은 부작용이 없는 장점이 있다. In addition, the manufacturing method of herbal tea for preventing and improving dementia according to the present invention has the advantage of having no side effects.
이하, 실시 예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시 예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시 예에 의해 제한되는 것은 아니다. Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, but the scope of the present invention is not limited by these examples.
멥쌀 30㎏ 및 물 30㎏을 혼합하여 내부온도가 100℃인 압력가열기에서 10분 동안 가열하고, 15℃ 및 120Pa 압력 하의 진공건조기에서 건조시킨 뒤, 100메쉬로 분쇄하여 팽화미를 제조하였다. 상기 팽화미 30㎏에 물 60ℓ를 가하고 증자기를 이용하여 1.2㎏/㎠, 110℃에서 30분 동안 증자한 후, 백국균(Aspergillus Kawachii) 80g을 가하고 26℃의 항온항습기에서 40시간 동안 배양하여 입국을 제조하였다. 상기 입국 4㎏, 물 6㎏ 및 효모 5g을 25~30℃에서 6일 동안 발효시켜 주모를 제조하였다. 상기 주모 10㎏, 상기 입국 50㎏, 물 70㎏, 참당귀 뿌리 1200g, 가시오갈피 뿌리 1000g, 은행나무 잎 1000g, 황기 800g, 두충 700g, 오미자 열매 640g, 원지 뿌리 640g, 석창포 뿌리 640g, 산사나무 열매 640g, 녹각 640g, 천궁 뿌리 500g, 프락토올리고당 500g, 용안육 열매 400g, 단삼 뿌리 390g, 감초 300g 및 스테비아추출물 10g을 23℃에서 6개월 동안 발효시켜 제1 사입을 얻었다. 상기 스테비아추출물은 스테비아 잎 10㎏을 함초수 20ℓ에 12시간 동안 침지한 후 건조하고 분쇄한 뒤, 상기 분쇄물을 초임계 추출기의 반응기에 투입하고 CO2 gas를 주입하면서 반응기를 회전시키고, 반응기 내 압력을 60기압으로 유지하면 CO2를 순환시켜 얻은 추출물을 여과하고 동결건조한 후 분말화하며 제조하였다. 상기 함초수는 함초 80중량%, 매실 15중량% 및 오미자 5중량%를 혼합한 혼합물 100중량부에 구기자추출액 1,000중량부를 가하고 100~105℃에서 4~6시간 동안 가열한 후 여과하여 제조하였다. 상기 구기자추출액은 구기자 100중량부에 물 300~400중량부를 가하고 95~105℃에서 1~2시간 동안 가열한 후 여과하여 제조하였다. 상기 제1 사입 130㎏, 팽화미 100㎏, 물 160㎏ 및 정제효소 150g을 15℃에서 3일 동안 발효시켜 제2 사입을 제조하였다. 상기 제2 사입을 100℃에서 40분 동안 가열하여 치매 예방 및 개선용 한방차를 제조하였다. 30 kg of non-glutinous rice and 30 kg of water were mixed, heated for 10 minutes in a pressure heater with an internal temperature of 100 ° C, dried in a vacuum dryer at 15 ° C and 120 Pa pressure, and then pulverized into 100 mesh to prepare puffed rice. After adding 60ℓ of water to 30kg of the puffed rice and increasing it using a steamer at 1.2kg/cm2 at 110 ° C for 30 minutes, 80 g of Aspergillus Kawachii was added and cultured for 40 hours in a thermo-hygrostat at 26 ° C. was manufactured. 4 kg of the above entry, 6 kg of water, and 5 g of yeast were fermented at 25 to 30 ° C. for 6 days to prepare stock hair. 10 kg of above hair, 50 kg of above seaweed, 70 kg of water, Angelica root 1200 g, Ginkgo ginseng root 1000 g, Ginkgo leaf 1000 g, Astragalus 800 g, Eucommia 700 g, Schisandra fruit 640 g, Wonji root 640 g, Iris root 640 g, Hawthorn fruit 640g, antler horn 640g, cnidium root 500g, fructooligosaccharide 500g, longan meat 400g, danseng root 390g, licorice 300g, and stevia extract 10g were fermented at 23° C. for 6 months to obtain a first insert. The stevia extract was immersed in 10 kg of stevia leaves in 20 L of seaweed water for 12 hours, dried and pulverized, and then the pulverized product was put into a reactor of a supercritical extractor, and the reactor was rotated while injecting CO 2 gas, When the pressure was maintained at 60 atm, the extract obtained by circulating CO 2 was filtered, freeze-dried, and then powdered. The glasswort water was prepared by adding 1,000 parts by weight of goji berry extract to 100 parts by weight of a mixture of 80% by weight of seaweed, 15% by weight of plum, and 5% by weight of Schisandra chinensis, heated at 100 to 105 ° C. for 4 to 6 hours, and then filtered. The goji berry extract was prepared by adding 300 to 400 parts by weight of water to 100 parts by weight of goji berry, heating at 95 to 105 ° C. for 1 to 2 hours, and then filtering. 130 kg of the first feed, 100 kg of puffed rice, 160 kg of water, and 150 g of purified enzyme were fermented at 15 ° C. for 3 days to prepare a second feed. The second injection was heated at 100 ° C. for 40 minutes to prepare herbal tea for preventing and improving dementia.
실시예 1에서, 상기 제2 사입 100중량부에 상기 제2 사입 100중량부에 톱니모자반추출물 3중량부, 마가목추출물 3중량부 및 금은화추출물 3중량부를 추가적으로 포함한 것을 제외하고 나머지는 동일하게 하여 치매 예방 및 개선용 한방차를 제조하였다. 상기 톱니모자반추출물은 톱니모자반 100g에 2ℓ의 30%(v/v) 에탄올 수용액에 넣고 25℃에서 24시간 동안 추출하여 제조하였다. 상기 마가목추출물은 마가목 100g에 2ℓ의 50%(v/v) 에탄올 수용액에 넣고 35℃에서 24시간 동안 추출하여 제조하였다. 상기 금은화추출물은 금은화 100g에 2ℓ의 70%(v/v) 에탄올 수용액에 넣고 40℃에서 24시간 동안 추출하여 제조하였다. In Example 1, except for additionally including 3 parts by weight of sawtooth extract, 3 parts by weight of mountain ash extract, and 3 parts by weight of silver flower extract in 100 parts by weight of the second injection, 100 parts by weight of the second injection, the rest was the same. Herbal tea for prevention and improvement was prepared. The cap-tooth extract was prepared by adding 100 g of cap-tooth cap to 2 liters of 30% (v/v) ethanol aqueous solution and extracting at 25° C. for 24 hours. The rowan extract was prepared by adding 100 g of rowan tree to 2 liters of 50% (v/v) ethanol aqueous solution and extracting at 35° C. for 24 hours. The gold and silver flower extract was prepared by adding 2 liters of 70% (v/v) ethanol solution to 100 g of gold and silver flowers and extracting at 40° C. for 24 hours.
[비교예 1][Comparative Example 1]
분쇄한 상황버섯 200g에 70% 에탄올 500㎖를 가한 후 초음파 파쇄기를 이용하여 실온에서 2시간 동안 추출한 후 여과하여 감압 건조시켜 70% 에탄올 가용추출물인 상황버섯 조추출물 분말 15.7g을 얻었다.After adding 500 ml of 70% ethanol to 200 g of pulverized Phellinus Phellinus, extraction was performed at room temperature for 2 hours using an ultrasonic crusher, followed by filtration and drying under reduced pressure to obtain 15.7 g of crude extract powder of Phellinus Phellinus, which is a 70% ethanol-soluble extract.
[실험예 1][Experimental Example 1]
실시예 1, 2에서 얻어진 한방차 및 비교예 1의 상황버섯 추출물에 대하여 아세틸콜린에스테라제 활성저해효과를 측정하여 그 결과를 표 1에 나타내었다.The herbal tea obtained in Examples 1 and 2 and the Phellinus Phellinus extract of Comparative Example 1 were measured for acetylcholinesterase activity inhibitory effect, and the results are shown in Table 1.
아세틸콜린에스테라제 저해활성실험에서 효소활성은 엘만(Ellman) 방법에 따라 기질인 아세틸티오콜린 요오드(acetylthiocholine iodide)가 아세틸콜린에스테라제에 의해 가수분해되어 유리되어 나오는 티오콜린(thiocholine)을 DTNB(디티오니트로벤조산)와 반응시켜 생성되는 디티오 화합물과 니트로벤조산의 티오음이온을 405nm UV로 검출하여 효소활성을 측정하고 아세틸콜린에스테라제 저해 물질로 알려진 타크린(tacrine; 1,2,3,4-테트라히드로-9-아크리딘아민)에 의한 저해활성과 비교하여 저해활성 수준을 평가하였다.In the acetylcholinesterase inhibitory activity test, the enzymatic activity was determined according to Ellman's method by hydrolyzing the substrate acetylthiocholine iodide by acetylcholinesterase to release thiocholine from DTNB. (Dithionitrobenzoic acid) and the thioanion of nitrobenzoic acid and the dithio compound produced by reaction were detected with 405 nm UV to measure the enzyme activity, and tacrine (1,2,3) known as an acetylcholinesterase inhibitor ,4-tetrahydro-9-acridinamine) was compared with the inhibitory activity level to evaluate the level of inhibitory activity.
실시예 1, 2의 한방차 및 비교예 1의 상황버섯 추출물을 각각 50mg/㎖ 농도로 함유한 DMSO 용액과 비교군으로 타크린(SIGMA-ALDRICH)을 2㎎/㎖ 농도로 함유한 DMSO 용액, 대조군으로 100% DMSO를 250(㎍/㎖) 농도가 되도록 인산완충액 (0.1M, pH 8.0)으로 희석한 후 시료별로 10㎕씩을 취하여 시험관에 담고 50mM 디티오비스-니트로벤조산(Dithiobis-nitrobenzoic acid) 용액 5㎕, 인산완충액(0.1M, pH 8.0) 132.5㎕ 및 50unit/㎖ 아세틸콜린 에스테라제 효소액 2.5㎕(SIGMA-ALDRICH)을 가하여 25℃ 항온기에서 5분간 반응시킨 후 분광광도계를 이용하여 405nm에서 흡광도를 측정하고 0.1mM 아세틸티오콜린 요오드 (acetylthiocholine Iodide)용액 50㎕ 가한 후 25℃ 항온기에서 3분간 반응시키고 405nm에서 흡광도를 측정하였다. 효소활성의 저해도는 하기 의 수학식을 통하여 계산하였다.A DMSO solution containing the herbal tea of Examples 1 and 2 and the Phellinus linteus extract of Comparative Example 1 at a concentration of 50 mg/mL, respectively, and a DMSO solution containing tacrine (SIGMA-ALDRICH) at a concentration of 2 mg/mL as a control group, As a control, 100% DMSO was diluted with phosphate buffer (0.1M, pH 8.0) to a concentration of 250 (μg/ml), and 10 μl of each sample was taken and placed in a test tube with 50 mM Dithiobis-nitrobenzoic acid solution. 5 μl, 132.5 μl of phosphate buffer (0.1M, pH 8.0) and 2.5 μl (SIGMA-ALDRICH) of 50 unit/ml acetylcholine esterase enzyme solution were added and reacted in an incubator at 25 ° C for 5 minutes, and then the absorbance at 405 nm was measured using a spectrophotometer was measured, 50 μl of 0.1 mM acetylthiocholine iodide solution was added, reacted in a 25° C. incubator for 3 minutes, and absorbance was measured at 405 nm. The degree of inhibition of enzyme activity was calculated through the following equation.
[수학식][mathematical expression]
활성저해도 (%) = (A/B) x 100%Activity inhibition (%) = (A / B) x 100%
A: 추출물을 포함하는 각 실험군에서 아세틸티오콜린 요오드 반응전 흡광도와 반응후 흡광도의 차A: Difference between absorbance before and after reaction with acetylthiocholine iodine in each experimental group including extract
B : 대조군에서 아세틸티오콜린 요오드 반응 전 흡광도와 반응 후 흡광도의 차B: Difference between absorbance before and after reaction with acetylthiocholine iodine in the control group
표 1에 나타낸 바와 같이, 실시예 1, 2의 한방차는 비교예 1의 상황버섯 추출물에 비하여 우수한 아세틸콜린에스테라제 저해활성을 나타내는 것을 확인할 수 있다.As shown in Table 1, it can be confirmed that the herbal teas of Examples 1 and 2 exhibit superior acetylcholinesterase inhibitory activity compared to the Sanghwang mushroom extract of Comparative Example 1.
실시예 1에서, 상기 한방차 100중량부에 모링가 추출발효물 1중량부, 저령 추출발효물 1중량부 및 꾸지뽕청 1중량부를 추가적으로 포함한 것을 제외하고 나머지는 동일하게 하여 치매 예방 및 개선용 한방차를 제조하였다. 상기 모링가 추출발효물은 모링가잎 100중량부에 80%(v/v) 에탄올 300중량부를 넣고 16시간 초음파 추출한 모링가잎 추출액 100중량부에 황국균 3중량부를 첨가하고 20℃에서 30시간 동안 발효시켜 제조하였다. 상기 저령 추출발효물은 저령 100중량부에 70%(v/v) 에탄올 600중량부를 넣고 70℃에서 24시간 동안 추출한 저령 추출액 100중량부에 혼합균 3중량부를 첨가하고 20℃에서 14시간 동안 발효시켜 제조하였다. 상기 혼합균은 유산균 65중량%, 홍국균 25중량% 및 고초균 10중량%를 혼합하여 제조하였다. 상기 꾸지뽕청은 꾸지뽕 열매 100중량부에 물 900중량부를 가하고 100℃에서 4시간 동안 추출한 후 50℃에서 저온진공 농축하여 70Brix의 꾸지뽕 농축액을 제조한 후, 75℃에서 30분 동안 가열하여 제조하였다.In Example 1, except that 100 parts by weight of the herbal tea additionally included 1 part by weight of fermented moringa extract, 1 part by weight of fermented fermented extract, and 1 part by weight of kkujippong extract, the rest was the same to prevent and improve dementia. tea was made. The fermented Moringa extract was added with 300 parts by weight of 80% (v/v) ethanol to 100 parts by weight of Moringa leaves, added 3 parts by weight of Hwanggukgyun to 100 parts by weight of Moringa leaf extract ultrasonically extracted for 16 hours, and stirred at 20 ° C for 30 hours. It was prepared by fermentation. The jeoryeong extract fermented product was added with 600 parts by weight of 70% (v / v) ethanol to 100 parts by weight of jeoryeong, and 3 parts by weight of the mixed bacteria was added to 100 parts by weight of jeoryeong extract extracted at 70 ° C for 24 hours and fermented at 20 ° C for 14 hours. It was prepared by The mixed bacteria was prepared by mixing 65% by weight of lactic acid bacteria, 25% by weight of Honggukgyun, and 10% by weight of Bacillus subtilis. The kkujippong extract was prepared by adding 900 parts by weight of water to 100 parts by weight of kkujippong fruit, extracting at 100 ° C. for 4 hours, and then concentrating in low temperature vacuum at 50 ° C. to prepare a 70Brix kkujippong concentrate, followed by heating at 75 ° C. for 30 minutes.
[비교예 2][Comparative Example 2]
인삼, 산수유, 모과, 오미자를 중량비 2:5:5:3의 비율로 혼합된 한약재에 증류수 1,300㎖을 가하여 열탕추출기에서 3시간 가열하여 얻은 추출액을 1회 여과한 후 감압 증류장치로 농축하고, 이를 다시 동결 건조기를 이용하여 완전 건조한 한약추출물을 deep-freezer 냉동고(-84℃)에 보관한 뒤, 희석하여 한약재를 이용한 치매 예방용 건강음료를 제조하였다.1,300 ml of distilled water was added to herbal medicines mixed with ginseng, cornus oil, quince, and Schisandra chinensis in a weight ratio of 2:5:5:3, heated in a hot water extractor for 3 hours, and the resulting extract was filtered once and concentrated with a vacuum distillation device, After this, the completely dried herbal extract was stored in a deep-freezer freezer (-84 ° C) using a freeze dryer, and then diluted to prepare a health drink for preventing dementia using herbal medicine.
[실험예 2][Experimental Example 2]
실시예 1, 3에서 제조한 한방차와 비교예 2에서 제조한 음료를 관능검사 요원으로 하여금 맛, 향 및 전체적인 기호도와 같은 관능검사를 실시하였다. 측정한 결과를 평균하여 표 2에 나타내었다. 관능검사는 2년 이상 관능검사 경험을 지닌 30명의 관능검사 요원으로 하여금 9점 척도법으로 하여 측정하였다. The oriental tea prepared in Examples 1 and 3 and the beverage prepared in Comparative Example 2 were subjected to sensory tests such as taste, aroma, and overall acceptability by a sensory test agent. The average of the measured results is shown in Table 2. The sensory test was measured using a 9-point scale method by 30 sensory test personnel with more than 2 years of sensory test experience.
상기 표 2를 통해 알 수 있는 바와 같이, 비교예 2의 음료에 비하여 본 발명에 따라 제조된 실시예 1, 3의 한방차가 관능검사의 전체적인 항목에서 높은 점수를 나타내고 있다.As can be seen from Table 2, compared to the beverage of Comparative Example 2, the herbal teas of Examples 1 and 3 prepared according to the present invention showed higher scores in all items of the sensory test.
Claims (5)
상기 입국 4㎏, 물 6㎏ 및 효모 5g을 25~30℃에서 6일 동안 발효시켜 주모를 제조하는 단계(단계 2);
상기 주모 10㎏, 상기 입국 50㎏, 물 70㎏, 참당귀 뿌리 1200g, 가시오갈피 뿌리 1000g, 은행나무 잎 1000g, 황기 800g, 두충 700g, 오미자 열매 640g, 원지 뿌리 640g, 석창포 뿌리 640g, 산사나무 열매 640g, 녹각 640g, 천궁 뿌리 500g, 프락토올리고당 500g, 용안육 열매 400g, 단삼 뿌리 390g, 감초 300g 및 스테비아추출물 10g을 22~23℃에서 6개월 동안 발효시켜 제1 사입을 얻는 단계(단계 3);
상기 제1 사입 130㎏, 팽화미 100㎏, 물 160㎏ 및 정제효소 150g을 15~16℃에서 3일 동안 발효시켜 제2 사입을 얻는 단계(단계 4); 및
상기 제2 사입을 100~105℃에서 30~40분 동안 가열하여 치매 예방 및 개선용 한방차를 제조하는 단계(단계 5);
를 포함하는,
치매 예방 및 개선용 한방차의 제조방법.
After adding 60ℓ of water to 30kg of puffed rice and increasing it using a steamer at 1.2kg/cm2 at 110℃ for 30 minutes, 80g of Aspergillus Kawachii was added and cultured for 40 hours in a thermo-hygrostat at 26℃ to enter the country. manufacturing step (step 1);
Fermenting 4 kg of the entry, 6 kg of water, and 5 g of yeast at 25 to 30 ° C. for 6 days to prepare main hair (step 2);
10 kg of above hair, 50 kg of above seaweed, 70 kg of water, Angelica root 1200 g, Ginkgo ginseng root 1000 g, Ginkgo leaf 1000 g, Astragalus 800 g, Eucommia 700 g, Schisandra fruit 640 g, Wonji root 640 g, Iris root 640 g, Hawthorn fruit 640g, antler horn 640g, cnidium root 500g, fructo-oligosaccharide 500g, longan meat 400g, dansam root 390g, licorice 300g, and stevia extract 10g fermented at 22-23 ° C. for 6 months to obtain a first stock (step 3);
fermenting 130 kg of the first feed, 100 kg of puffed rice, 160 kg of water, and 150 g of purified enzyme at 15-16° C. for 3 days to obtain a second feed (step 4); and
Preparing herbal tea for preventing and improving dementia by heating the second injection at 100 to 105 ° C. for 30 to 40 minutes (step 5);
including,
Manufacturing method of herbal tea for prevention and improvement of dementia.
상기 팽화미는 멥쌀 30㎏ 및 물 30㎏을 혼합하여 내부온도가 100℃인 압력가열기에서 10분 동안 가열하고, 15℃ 및 120Pa 압력 하의 진공건조기에서 건조시킨 뒤, 100~150메쉬로 분쇄하여 제조하는,
치매 예방 및 개선용 한방차의 제조방법.
The method of claim 1, wherein in step 1,
The expanded rice is prepared by mixing 30 kg of non-glutinous rice and 30 kg of water, heating for 10 minutes in a pressure heater with an internal temperature of 100 ° C, drying in a vacuum dryer at 15 ° C and a pressure of 120 Pa, and then pulverizing into 100 to 150 mesh ,
Manufacturing method of herbal tea for prevention and improvement of dementia.
상기 스테비아추출물은 스테비아 잎 10㎏을 함초수 20ℓ에 12시간 동안 침지한 후 건조하고 분쇄한 뒤, 상기 분쇄물을 초임계 추출기의 반응기에 투입하고 CO2 gas를 주입하면서 반응기를 회전시키고, 반응기 내 압력을 60기압으로 유지하면 CO2를 순환시켜 얻은 추출물을 여과하고 동결건조한 후 분말화하며 제조하되,
상기 함초수는 함초 80중량%, 매실 15중량% 및 오미자 5중량%를 혼합한 혼합물 100중량부에 구기자추출액 1,000중량부를 가하고 100~105℃에서 4~6시간 동안 가열한 후 여과하여 제조하며,
상기 구기자추출액은 구기자 100중량부에 물 300~400중량부를 가하고 95~105℃에서 1~2시간 동안 가열한 후 여과하여 제조하는,
치매 예방 및 개선용 한방차의 제조방법.
The method of claim 1, wherein in step 3,
The stevia extract was immersed in 10 kg of stevia leaves in 20 L of seaweed water for 12 hours, dried and pulverized, and then the pulverized product was put into a reactor of a supercritical extractor, and the reactor was rotated while injecting CO 2 gas, When the pressure is maintained at 60 atmospheres, the extract obtained by circulating CO 2 is filtered, freeze-dried, and then powdered to prepare,
The seaweed water is prepared by adding 1,000 parts by weight of goji berry extract to 100 parts by weight of a mixture of 80% by weight of seaweed, 15% by weight of plum, and 5% by weight of Schizandra chinensis, heated at 100 to 105 ° C. for 4 to 6 hours, and then filtered.
The goji berry extract is prepared by adding 300 to 400 parts by weight of water to 100 parts by weight of goji berry, heating at 95 to 105 ° C. for 1 to 2 hours, and then filtering.
Manufacturing method of herbal tea for prevention and improvement of dementia.
상기 단계 4 이후에, 상기 제2 사입 100중량부에 톱니모자반추출물 1~3중량부, 마가목추출물 1~3중량부 및 금은화추출물 1~3중량부를 추가적으로 포함하되,
상기 톱니모자반추출물은 톱니모자반 100g에 2ℓ의 30%(v/v) 에탄올 수용액에 넣고 25℃에서 24시간 동안 추출하여 제조하며,
상기 마가목추출물은 마가목 100g에 2ℓ의 50%(v/v) 에탄올 수용액에 넣고 35℃에서 24시간 동안 추출하여 제조하며,
상기 금은화추출물은 금은화 100g에 2ℓ의 70%(v/v) 에탄올 수용액에 넣고 40℃에서 24시간 동안 추출하여 제조하는,
치매 예방 및 개선용 한방차의 제조방법.
According to claim 1,
After the step 4, 1 to 3 parts by weight of a sawtooth cap extract, 1 to 3 parts by weight of a rowan extract, and 1 to 3 parts by weight of a silver flower extract are additionally included in 100 parts by weight of the second injection,
The cap and cap extract is prepared by adding 100 g of cap and cap in 2 liters of 30% (v/v) ethanol aqueous solution and extracting at 25° C. for 24 hours,
The rowan extract is prepared by adding 100 g of rowan tree to 2 liters of 50% (v/v) ethanol aqueous solution and extracting at 35° C. for 24 hours,
The gold and silver flower extract is prepared by adding 2 liters of 70% (v / v) ethanol aqueous solution to 100 g of gold and silver flowers and extracting at 40 ° C. for 24 hours.
Manufacturing method of herbal tea for prevention and improvement of dementia.
상기 단계 5 이후에, 상기 한방차 100중량부에 모링가 추출발효물 0.1~1중량부, 저령 추출발효물 0.1~1중량부 및 꾸지뽕청 0.1~1중량부를 추가적으로 포함하되,
상기 모링가 추출발효물은 모링가잎 100중량부에 80%(v/v) 에탄올 300~400중량부를 넣고 14~16시간 초음파 추출한 모링가잎 추출액 100중량부에 황국균 1~3중량부를 첨가하고 15~20℃에서 30~32시간 동안 발효시켜 제조하며,
상기 저령 추출발효물은 저령 100중량부에 70%(v/v) 에탄올 600~700중량부를 넣고 65~70℃에서 24~25시간 동안 추출한 저령 추출액 100중량부에 혼합균 1~3중량부를 첨가하고 15~20℃에서 14~15시간 동안 발효시켜 제조하며,
상기 혼합균은 유산균 60~70중량%, 홍국균 20~30중량% 및 고초균 5~15중량%를 포함하며,
상기 꾸지뽕청은 꾸지뽕 열매 100중량부에 물 800~900중량부를 가하고 100~105℃에서 4~6시간 동안 추출한 후 50~60℃에서 저온진공 농축하여 70~75Brix의 꾸지뽕 농축액을 제조한 후, 70~75℃에서 25~30분 동안 가열하여 제조하는,
치매 예방 및 개선용 한방차의 제조방법.According to claim 1,
After step 5, 0.1 to 1 part by weight of fermented moringa extract, 0.1 to 1 part by weight of fermented extract of moringa, and 0.1 to 1 part by weight of kkujippong extract are additionally included in 100 parts by weight of the herbal tea,
The fermented Moringa extract is added with 300 to 400 parts by weight of 80% (v / v) ethanol to 100 parts by weight of Moringa leaves, and 1 to 3 parts by weight of H. It is prepared by fermentation at 15 to 20 ° C for 30 to 32 hours,
The jeoryeong extract fermented product is added to 100 parts by weight of 70% (v / v) ethanol, 600 to 700 parts by weight of 70% (v / v) ethanol, and 1 to 3 parts by weight of mixed bacteria added to 100 parts by weight of jeoryeong extract extracted at 65 to 70 ° C for 24 to 25 hours. and fermented at 15 to 20 ° C for 14 to 15 hours,
The mixed bacteria include 60 to 70% by weight of lactic acid bacteria, 20 to 30% by weight of Honggukgyun, and 5 to 15% by weight of Bacillus subtilis,
The kkujippong cheong is added to 800 to 900 parts by weight of water to 100 parts by weight of kkujippong fruit, extracted at 100 to 105 ° C for 4 to 6 hours, and then concentrated in low temperature vacuum at 50 to 60 ° C. After preparing a concentrate of 70 to 75 Brix, 70 Prepared by heating at ~75 ° C for 25 to 30 minutes,
Manufacturing method of herbal tea for prevention and improvement of dementia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210066936A KR102640050B1 (en) | 2021-05-25 | 2021-05-25 | Manufacturing method of Medical Herb Tea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210066936A KR102640050B1 (en) | 2021-05-25 | 2021-05-25 | Manufacturing method of Medical Herb Tea |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220159536A true KR20220159536A (en) | 2022-12-05 |
KR102640050B1 KR102640050B1 (en) | 2024-02-28 |
Family
ID=84391905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210066936A KR102640050B1 (en) | 2021-05-25 | 2021-05-25 | Manufacturing method of Medical Herb Tea |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102640050B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020035368A (en) * | 2000-11-06 | 2002-05-11 | 최태규 | Method For Producing Refined Rice Wine Made From Swelled Rice |
KR20070105679A (en) * | 2006-04-27 | 2007-10-31 | 한국과학기술연구원 | A composition for improving memory |
KR20140039553A (en) * | 2012-09-24 | 2014-04-02 | 권미송 | Medical wine and its manufacturing method |
KR102092509B1 (en) | 2019-09-02 | 2020-03-23 | 강기원 | Food composition for preventing and improving of dementia |
-
2021
- 2021-05-25 KR KR1020210066936A patent/KR102640050B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020035368A (en) * | 2000-11-06 | 2002-05-11 | 최태규 | Method For Producing Refined Rice Wine Made From Swelled Rice |
KR20070105679A (en) * | 2006-04-27 | 2007-10-31 | 한국과학기술연구원 | A composition for improving memory |
KR20140039553A (en) * | 2012-09-24 | 2014-04-02 | 권미송 | Medical wine and its manufacturing method |
KR102092509B1 (en) | 2019-09-02 | 2020-03-23 | 강기원 | Food composition for preventing and improving of dementia |
Also Published As
Publication number | Publication date |
---|---|
KR102640050B1 (en) | 2024-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101946236B1 (en) | Cosmetical composition with antimicrobial and antioxidant using natural plant extract and cosmetics comprising thereof | |
KR101952695B1 (en) | Composition having anti-wrinkle effects using the natural plant extract and cosmetic composition comprising the same | |
KR20150045036A (en) | Composition comprising an extract of Cynanchi wilfordii for preventing or treating of climacteric disorder | |
CN103168890A (en) | Medlar coreopsis tinctoria flower tea | |
KR101863722B1 (en) | Functional cosmetic composition containing extracts of natural products | |
CA3152970A1 (en) | Tea composition having efficacy for preventing or improving respiratory diseases, and pharmaceutical composition comprising same | |
KR20080090806A (en) | Cosmetic composition containing natural product extracts for restoring skin condition | |
JP2009256272A (en) | Atp production promoting agent and epidermal cell activation agent | |
KR102004366B1 (en) | A cosmetic composition comprising centipeda minima extract | |
KR101980887B1 (en) | A cosmetic composition comprising trichosanthes kirilowii extract and metaplexis japonica extract | |
KR20220030505A (en) | Salad Dressing Sauce and Manufacturing Method of thereof | |
KR101673204B1 (en) | Health beverage using natural materials with protection of brain cells | |
KR101988295B1 (en) | Composition for skin moisturizing and anti-wrinkle comprising herbal medicine mixed extract as effective component | |
KR102356517B1 (en) | Health supplement composition using herbal medicine and health supplement food using the same | |
KR20200107444A (en) | The skin cosmetic composition for anti-oxidation and anti-wrinkle of skin comprising natural complex extracts | |
KR102640050B1 (en) | Manufacturing method of Medical Herb Tea | |
KR101375347B1 (en) | The method for manufacuting red ginseng drink with medicinal herb, and the red ginseng drink made by the method | |
Roy et al. | Herbs Used In Peptic Ulcer: A Review. | |
KR20150037106A (en) | Manufacturing method of pills containing wild ginseng extracts, herb extracts and active ingredients and pills containing wild ginseng extracts, herb extracts and active ingredients manufactured by the same | |
KR102520686B1 (en) | The health drink containing mainly Gastrodia elata Blume | |
KR102640760B1 (en) | Manufacturing method of Medical Herb Tea | |
KR102568831B1 (en) | Manufacturing Method of Wild Ginseng Syrup | |
KR20190129367A (en) | Preparation of Mixed Tea Composition Comprising Aloeswood | |
KR102365198B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng | |
KR102491631B1 (en) | Manufacturing Method of Wild Ginseng Syrup |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |